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ABSTRACT 
Maganizo Brave Chagomerana: Option B+ in Malawi:  Antiretroviral therapy for prevention of 
mother-to-child HIV transmission and its effects on preterm birth and female-to-male HIV 
transmission 
 (Under the direction of Kimberly A. Powers) 
 
Large number of new and prevalent HIV infections among reproductive-aged women in 
sub-Saharan Africa makes prevention of mother-to-child HIV transmission (PMTCT) a major 
public health priority. Option B+ is a simplified approach to PMTCT that recommends universal 
life-long ART for pregnant and breastfeeding women regardless of HIV disease stage or CD4 
count. This approach is expected to help bring an end to new pediatric HIV infections and 
substantially improve maternal health in settings with high HIV burdens. However, the effect of 
ART initiation during pregnancy in the Option B+ era on birth outcomes and female-to-male HIV 
transmission is not well known.  
We used maternity-ward data from Bwaila Hospital in Lilongwe, Malawi to estimate the 
risk of preterm birth among HIV-infected women.   The risk of preterm birth was similar in 
women who had initiated ART at any point prior to delivery compared to those who never 
initiated ART (adjusted Risk Ratio (aRR) = 0.88; 95% CI: 0.65 – 1.19). No clear trend between 
timing of ART and risk of preterm birth was observed. ART initiation at any point before delivery 
was strongly protective against extremely to very preterm birth (27 – 32 weeks gestation) (aRR 
= 0.43; 95% CI: 0.26 – 0.72)  
Using mathematical modeling we estimated the female-to male HIV infections using two 
PTMTC approaches, Option B and Option B+ in the period 2011 - 2020. The estimated relative 
incidence (RI) under Option B+ was 4% lower (median RI = 0.96; 95% CI: 0.94 – 0.97) in 2015  
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and was projected to be 7% lower (median RI = 0.93; 95% CI: 0.90 – 0.95) by 2020 compared 
to the Option B in which ART uptake values in the period 2011-2020 assumed to be the same 
for Option B as those assumed for Option B+. When Option B ART uptake values in the period 
2011-2020 were assumed to remain at 2011 levels, the estimated RI under Option B+ was 14% 
lower (median RI = 0.86; 95% CI: 0.84 – 0.88) in 2015 and was projected to be 21% lower 
(median RI = 0.79; 95% CI: 0.74 – 0.83) by 2020. 
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CHAPTER ONE: SPECIFIC AIMS 
Mother-to-child HIV transmission (MTCT) can occur in-utero, intrapartum or postnatally 
during breastfeeding. Life-long triple antiretroviral (ARV) treatment for HIV-infected pregnant 
women with CD4 < 350 cells per mm3, and prophylaxis (Option  A) or ARV (Option  B) during 
pregnancy for women with CD4 ≥ 350 cells per mm3 starting as early as 14 weeks of gestation, 
has been successful in reducing MTCT.1-4 However, the requirement to measure CD4 cell count 
to determine eligibility for starting treatment or stopping of treatment after breastfeeding has 
been a challenge in most resource-poor settings where CD4 cell count testing is not readily 
available. 
In 2011, the Malawi government proposed and started implementing a new and 
simplified approach for prevention of mother-to-child transmission (PMTCT) called Option B+, in 
which all confirmed HIV-infected pregnant or breastfeeding women are started on antiretroviral 
therapy (ART) for life regardless of World Health Organization (WHO) clinical stage or CD4 cell 
count.5  Since the introduction of PMTCT Option B+ in Malawi, the number of pregnant or 
breastfeeding women on ART has dramatically increased.6,7   WHO now recommends the 
Option B+ strategy to all countries with a generalized HIV epidemic.8 Besides preventing vertical 
transmission, the Option B+ program has other potential ancillary benefits.  When properly 
adhered to, ART can improve infant and maternal health, prevent sexual HIV transmission, and 
prevent MTCT in subsequent pregnancies.9-11  
The Option B+ program in Malawi has now matured, providing an opportunity to assess 
the relationship between time of ART initiation during pregnancy and birth outcomes and to 
evaluate the ancillary benefit of lifelong ART for pregnant and breastfeeding women on female-
to-male HIV transmission (as compared to more limited-duration ART under the Option B 
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approach). This assessment will help to define the optimal time for ART initiation among pregnant 
women and quantify the ancillary benefit of lifelong ART under Option B+ on heterosexual HIV 
transmission in Malawi and similar countries planning to start Option B+. 
 
Aim 1: Determine the effect of ART initiation during or before pregnancy on preterm birth 
among pregnant women in the Option B+ era. 
 
Hypothesis: We hypothesize that a) HIV-infected pregnant women who initiate ART during or 
before pregnancy have a lower risk of preterm delivery than women who are not on ART during 
pregnancy, and b) earlier ART initiation is associated with a lower risk of preterm birth than is 
later ART initiation. 
 
Overview: We will conduct a secondary analysis of data collected at delivery from HIV-infected 
women delivering at ≥ 27 weeks of gestation between April 1, 2012 and November 15, 2015 at 
Bwaila Hospital in Lilongwe, Malawi. Among women on ART at delivery, we will restrict our 
analysis to women who initiated ART before 27 weeks of gestation. The outcome of interest will 
be preterm birth, defined as live birth at ≥27 and <37 weeks of gestation. The primary exposures 
will be ART use and time of ART initiation (never, before pregnancy, 1st trimester, 2nd trimester). 
We will use log-binomial regression models to estimate the preterm birth risk ratios comparing 
women who were on ART during delivery (and according to time of ART initiation) to women 
who never initiated ART.  
 
Aim 2: Develop a mathematical model to quantify the ancillary benefit of Option B+ (relative to 
Option B) on heterosexual transmission in Lilongwe, Malawi. 
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Hypothesis: Life-long ART initiated among HIV-infected pregnant women under Option B+ can 
reduce the incidence of HIV in the general population through reduced transmission from HIV-
infected women to HIV-uninfected men during and beyond the period of pregnancy and 
breastfeeding. 
 
Overview: We will develop a deterministic mathematical model to study the effect of Option B+ 
on female-to-male HIV transmission among sexually active women aged 15 – 49 years in 
Lilongwe, Malawi. The model will describe the dynamics of HIV infection and progression, HIV 
treatment, and pregnancy and breastfeeding according to age and calendar time among 
sexually active women. HIV transmission to men will be specified as a function of female HIV 
prevalence and the relative infectiousness of HIV according to disease stage, pregnancy status, 
and treatment status, allowing comparison of estimated female-to-male transmission under 
Option B+ versus Option B.  . 
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
The burden of HIV / AIDS in sub-Saharan Africa 
In 2013, an estimated 24.7 million people in sub-Saharan Africa were living with HIV, 
accounting for 71% of the estimated HIV-infected population worldwide. Of the 24.7 million 
adults and children living with HIV, 1.5 million were newly infected, reflecting high HIV incidence 
in this setting. The HIV pandemic in the region has disproportionately affected women; 58% of 
people living with HIV in sub-Saharan Africa are women.12 The high HIV prevalence among 
women, the majority of whom are reproductive-aged, has resulted in substantial maternal 
morbidity and mortality, adverse birth outcomes, and mother-to-child HIV transmission.  
 
 Maternal morbidity and mortality 
 HIV is the leading cause of death among women during pregnancy and the postpartum 
period in sub-Saharan Africa. At least 25% of all pregnancy-related deaths in the region have 
been attributed to HIV infection.13 In 2010, sub-Saharan Africa contributed about 56% to the 
total global maternal deaths. 17,000 of these maternal deaths in sub-Saharan Africa were 
attributed to HIV, representing 91% of all HIV-related maternal deaths in the world.14,15  
The exact cause of maternal mortality among women with HIV/AIDS is still unclear. HIV-
infected women with a low CD4 cell count during pregnancy or postpartum are more likely to die 
compared to women with higher CD4 cell counts.16 Maternal HIV infection during pregnancy 
decreases the percentage and absolute number of CD4 cells.13 The decrease in CD4 cell count 
may result in a greater risk of opportunistic infections not related to pregnancy, leading to fast 
HIV disease progression and eventually death. Faster HIV disease progression in pregnancy  
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(vs. not during pregnancy) is more common in developing countries (OR = 3.71; 95% CI: 1.82 - 
7.75) compared to developed countries (OR = 0.55; 95% CI: 0.27 - 1.11).17 Poor nutrition and 
limited access to health care during pregnancy are some of the factors modifying the 
association between pregnancy and HIV disease progression in developing (versus developed) 
countries.18,19  
 
Adverse pregnancy outcomes in HIV-infected women 
 Adverse birth outcomes, including preterm births, stillbirths, and low birthweight births, 
can be physically and emotionally devastating to the mother. Maternal nutritional status before 
and during pregnancy has been the major determinant of gestational outcomes worldwide.20-22 
In areas where poor nutrition is common, the prevalence of adverse birth outcomes is generally 
high. For example, more than 60% of preterm babies worldwide are born in low-income 
countries of south Asia and sub-Saharan Africa.23 
 
Preterm birth 
 Preterm birth, often defined as being born before 37 weeks of gestation, is the second-
leading cause of death in children under 5 years, and the single most important cause of death 
within the first month of life.24 Worldwide, preterm births account for 75% of all perinatal 
mortality.25,26 Out of the estimated 15 million infants born preterm in 2010, more than 1 million 
died as a result of being born premature.23,27 
Very little is known about the causes and mechanisms of preterm birth.27 In areas where 
HIV is endemic, HIV infection during pregnancy has emerged as a major risk factor for preterm 
birth. In sub-Saharan Africa, the risk of having a premature baby among HIV-infected women 
has been estimated to be at least double the risk of having a premature baby among HIV-
uninfected women.28-30  
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Stillbirths 
Stillbirths constitute the majority of the world's perinatal deaths. In 2009, at least 2.64 
million stillbirths (range 2.14 million to 3.82 million), defined as ≥1000g birthweight or ≥28 weeks 
of gestation, were estimated to have occurred worldwide. Of the 2.64 million stillbirths, more 
than 76% occurred in South Asia and sub-Saharan Africa, where skilled birth attendants and 
access to caesarean sections are much lower than in developed countries. In sub-Saharan 
Africa alone, 934,600 of the 33 million estimated total births in 2009 were stillbirths.31  
 While fewer skilled birth attendants and lack of facilities for caesarean sections are 
contributing to the large number of stillbirths in sub-Saharan Africa,32 the high prevalence of HIV 
among reproductive-aged women may also be contributing to the increase in the number of 
stillbirths. Studies in the region have found that the risk of having a stillbirth is higher among 
HIV-infected women compared to HIV-uninfected women.28 In a meta-analysis investigating the 
association between maternal HIV infection and perinatal outcomes, the odds of having a 
stillbirth among HIV-infected women was found to be at least three times the odds of having a 
stillbirth among HIV-uninfected women (OR = 3.91; 95% CI: 2.65 - 5.77).33 
 
Low birthweight 
Low birthweight (LBW) is not only an important risk factor for neonatal mortality but also 
a major determinant of post-neonatal infant mortality and infant and childhood morbidity.25 A 
newborn baby is marked as having LBW when it weighs less than 2500g within the first hour of 
life, irrespective of gestational age. Globally, more than 20 million infants are born with LBW; 
95.6% of these infants are born in the developing countries. The developing regions of Asia and 
Africa contribute 92% of all LBW babies born in developing countries.34 
LBW is caused by short gestational period (preterm birth), intrauterine growth restriction 
(IUGR) or a combination of preterm birth and IUGR.20,21  Whether the infants are preterm or not, 
IUGR results in infants who are small-for-gestational-age (SGA). While LBW is defined as 
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infants who weigh < 2500g at birth, SGA is based on the percentile of the birthweight-for-
gestational age; defined as birthweight below the10th percentile of the expected birthweight for 
any growth week. Infants with prematurity-related LBW have an increased risk of developing 
conditions that are related to physiological immaturity compared to those with IUGR related 
LBW. Most infants born with IUGR-related LBW show growth and subtle neurological cognitive 
deficiencies.20 In general, SGA infants have poorer outcomes than appropriate-for-gestational-
age (AGA) infants.35  
The prevalence and causes of LBW vary in different regions of the world. Developing 
countries have a higher prevalence of LBW than developed countries. While most of the LBW 
are due to preterm birth in developed countries, in developing countries LBW is often associated 
with IUGR.36 In sub-Saharan Africa, where the prevalence of HIV infection is also high, HIV 
infection has been associated with both LBW and SGA.28-30,37-40 For example, in a case-control 
study of 177 HIV-seropositive and 326 seronegative women and their newborns in Nairobi, 
Kenya, the birthweight was less than 2500 g in 9% of cases and 3% of controls (OR = 3.0; 95% 
CI: 1.3 - 6.7).39 In South Africa, the risk ratio of having SGA infants when HIV-infected women 
were compared with HIV-uninfected women was estimated to be 1.28 (95%CI: 1.6 - 1.53).40 
 
Risk factors for adverse birth outcomes among HIV-infected pregnant women 
 In addition to other established risk factors associated with adverse birth outcomes such 
as socioeconomic status, ethnicity, multiple pregnancy, parity, substance abuse, intrauterine 
infections, and infection with sexually transmitted diseases, 20,26,41  high HIV viral load and  low 
CD4 cell count are known to increase the risk of adverse pregnancy outcomes among HIV-
infected pregnant women.   
Without HIV treatment, the level of HIV viral load and CD4 cell count varies over the 
course of HIV infection. In a typical course of HIV infection, there is a widespread dissemination 
of the virus and a sharp decrease in CD4 cell count in peripheral blood during primary infection. 
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When the immune system starts to respond to the infection, the levels of detectable viremia 
start to decrease.  After several weeks, the CD4 cell count starts to decrease again and this 
continues until it reaches a critical low level below which the HIV virus starts to replicate and 
spread again.42 The primary and late stage periods of HIV infection, characterized by high 
viremia, are particularly high-risk periods for poor birth outcomes among HIV-infected women. 
Among HIV-infected pregnant women, high HIV viral load significantly increases the risk 
of having a stillbirth. The risk of having a stillbirth among HIV-infected pregnant women with 
high viral load can be at least twice the risk of having a stillbirth among HIV-infected pregnant 
women with low viral load.43,44  HIV viral load has also been observed to have a similar effect on 
preterm birth and LBW.45 
Low CD4 cell count among HIV-infected pregnant women has also been associated with 
a significant increase in adverse birth outcomes. Studies of neonates from HIV-seropositive 
women in Sub-Sahara Africa have shown that mothers with low CD4 cell count were more likely 
to have infants with LBW compared to mothers who had higher CD4 cell count.39 Similar 
associations have been observed between CD4 cell count and stillbirth or preterm birth. 
 
Issues in measuring birth outcomes 
Accurately counting adverse birth outcomes is important for public health. These 
statistics provide an opportunity to set targets for interventions towards improving maternal and 
child health. However, measuring incidence or prevalence of birth outcomes and comparing 
them across countries has been a challenge. In particular, inconsistences in the definitions of 
birth outcomes and the use of different measurement approaches for the same outcomes in 
different countries have made comparison of birth outcome statistics difficult.  
Gestational age is an important factor in predicting date of delivery and identifying 
preterm or SGA infants. Unfortunately, in areas where ultrasound for dating pregnancy is not 
available, the gestational age is often inaccurate.46 In the absence of ultrasound for dating 
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pregnancy, last menstrual period (LMP) and lunar or menstrual cycles have been used. The use 
of date of LMP as the onset of pregnancy is prone to recall bias, as many women do not know 
the exact date they last had a menstrual period. In a study of infants born extremely preterm (< 
28 weeks)  in the Swedish national registry,  gestational age estimated by LMP for extremely 
preterm infants appeared to be longer than gestational age estimated by ultrasound (17.2% of 
the gestational ages measured by LMP  were longer than 27 weeks).47  Other variants of 
months used in some countries in counting duration of pregnancy such as lunar or menstrual 
cycles make correct calculation of pregnancy duration difficult. 
 Although stillbirths constitute the majority of the world's perinatal deaths, statistics on 
stillbirth are largely missing in most country or world health reports. In most developing 
countries, 80% of stillborn babies are disposed of without any recognition,46 resulting in fewer 
stillbirths recorded than actually observed worldwide.  
Different countries use different measures and cut-offs to classify a fetal death as 
stillbirth. According to International Classification of Diseases, 10th revision (ICD-10), a stillbirth 
is defined as any fetal death in the last two trimesters of pregnancy that satisfies any of the 
following three criteria: has a birthweight ≥500g, completed ≥ 22 weeks of gestational age, or 
has crown-heel length ≥ 25 cm. On the other hand, WHO defines any fetal death as stillbirth if it 
satisfies any of the following three criteria:  has birthweight ≥ 1000g, completed ≥28 weeks of 
gestation, or has body length ≥ 35cm. In some developed countries, fetal deaths as early as 18 
weeks are defined as stillbirths.48,49 
The reported number of stillbirths therefore can vary depending on the measure and cut-
off used in defining stillbirth. The use of weight, gestational age, or body length in classifying 
stillbirths may result in different counts of stillbirths. Even among those that use gestational age, 
the use of different gestational age cut-offs for defining stillbirth makes comparison of stillbirths 
across the world difficult. The use of a much higher gestational age or much lower gestational 
age in defining stillbirths can result in underestimating or overestimating stillbirths respectively.50   
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 LBW is an important factor in determining neonatal mortality and post-neonatal quality of 
life.51 However, worldwide estimates of incidence or prevalence of LBW are often 
unrepresentative. In sub-Saharan Africa, more than 40% of babies are born at home and 
without a skilled birth attendant, resulting in many infants that are not weighed.  Among the live 
births that are weighed, not all weight is measured within the first hour of life before significant 
postnatal weight loss has occurred. In addition to failure to weigh new born babies within the 
recommended period, different scales have been used to weigh new born babies. The use of 
different scales has contributed to distortion and errors in measuring birthweight. These 
inconsistences and errors are more common when the scales are not well calibrated or the 
readings are always rounded, as is the case where categorical scales are used. Although the 
use of chest circumference as a proxy measure for birthweight is recommended for babies that 
are not delivered at a health facility, it does not provide an accurate measure for birthweight.34  
There is a need to correctly classify LBW as either preterm SGA or term SGA. Correctly 
classifying LBW infants as preterm SGA and term SGA infants is important in studying the risk 
factors and understanding the prognosis associated with LBW. The difficulty in separating 
preterm infants, preterm SGA infants and term SGA infants has resulted in the incorrect 
comparison of risk factors for preterm birth and SGA births. While some studies have excluded 
preterm SGA infants in a study of the risk factors for preterm births compared with SGA births,52 
others have included preterm SGA births in both preterm birth and SGA births.53,54  
 
HIV mother-to-child transmission  
In 2011, 330,000 children acquired HIV infection worldwide. Among the children who 
acquired HIV infection in 2011, more than 90% lived in sub-Saharan Africa.55 The majority of 
HIV infections among children are acquired from their mothers during pregnancy, delivery or 
breastfeeding. In the absence of any intervention, approximately 13%–43% of the children born 
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to HIV-infected mothers are infected by the virus, depending on setting and duration of 
breastfeeding.56  
The exact timing for vertical transmission during pregnancy is not well understood. While 
a few studies have reported vertical transmission as early as the first trimester,57,58 the majority 
of studies have reported the occurrence of fetal infections during the second trimester or later.59-
61 When identifying prenatal transmission, it is often difficult to differentiate in utero from 
intrapartum transmissions. However, based on the time when HIV infection was detected in 
infants who were not exposed to breast milk (first two days of life versus after one week of life 
and by 6 weeks of age), about two thirds of perinatal vertical transmission appear to occur 
during labor.62-64  
 
Risk factors for HIV MTCT  
HIV MTCT is either due to existing HIV infection at conception or incident infection 
during pregnancy or breastfeeding. While some risk factors for HIV MTCT apply to all times of 
transmission, others are specific to prenatal, during labor and delivery or postnatal periods. 
 HIV viral load and immunological status of an HIV-infected woman during pregnancy, 
delivery or breastfeeding influences HIV vertical transmission. Higher maternal viral load in 
plasma, genitourinary tract or breast milk has been associated with a higher risk of vertical HIV 
transmission.65-68 Maternal immunological status has also been shown to influence the MTCT of 
HIV in both pregnant and breastfeeding women; lower maternal CD4 cell count has been shown 
to be associated with an increased risk of both perinatal and postnatal HIV MTCT.66,69-71     
 Infection with other sexually transmitted diseases in HIV-infected women increases the 
risk of HIV MTCT.72,73 The increase in risk may be due to enhanced HIV replication or effects of 
infection such as cervicitis, genital ulcers and chorioamnionitis. Rapid HIV replication may 
increase the viral load in the genital tract74 resulting in increased risk of transmission during 
pregnancy and delivery. Increased viral load in the presence of cervicitis and genital ulcers may 
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increase the risk of both intrauterine and intrapartum HIV transmission (especially in vaginal 
deliveries). Compromised integrity of the placental barrier by chorioamnionitis may facilitate free 
transfer of HIV across the placenta and may lead to HIV transmission intrapartum.70 
Premature infants born to HIV-infected women have an increased risk for HIV infection 
compared to full term infants.30,70,75-77 In a prospective study of pregnant women infected with 
HIV, infants born at 37 weeks of gestation or earlier were at higher risk of HIV-1 infection than 
infants born at 38 weeks of gestation or later (60% vs 22%).77 Since transfer of maternal 
antibodies to the fetus occurs late in pregnancy, most preterm infants are born before the 
adequate levels of maternal antibodies have been transferred.78 In HIV-infected pregnant 
women, such preterm infants are therefore more likely to be infected with HIV during delivery.  
During vaginal delivery, infants born to HIV-infected women are exposed to 
contaminated blood or cervical secretions.74 The exposure to contaminated blood and cervical 
fluids increases the risk of HIV transmission during the intrapartum period. A European study of 
singleton births of HIV-infected women showed that infants delivered through caesarean section 
have a lower risk of being infected with HIV than those delivered through the vagina (3.4% vs 
10.2%).75 In addition to exposure to blood and cervical fluids during vaginal delivery, prolonged 
duration of membrane rupture may be an important factor in HIV-transmission.63,76,79 This can 
explain why in a study of twins, the first born twin was more likely to be infected with HIV than 
the second-born twin.80   
 In most sub-Saharan Africa countries, breastfeeding is strongly encouraged for the first 
24 months of life because it satisfies the nutritional needs of the infant and helps to protect the 
infant against diarrheal and upper respiratory infections and deaths.81,82 Unfortunately, free HIV 
and HIV DNA are detected in breast milk of HIV-infected mothers.83,84 As a result, postnatal 
vertical transmission of HIV from mother to the child is more common in children who are 
breastfed compared to those who are not.71,85,86 In the absence of any intervention, 
breastfeeding by an infected mother increases the risk of mother-to-child transmission from 
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15%–30% in non-breastfeeding populations to 20%–45% in those who breastfeed.87 The lack of 
substitutes for breast milk in developing countries has therefore made the task of balancing the 
risk of HIV MTCT through breast milk against the substantial benefits of breastfeeding very 
challenging. 
Among infants who are breastfeeding, the risk of vertical HIV transmission depends on 
the duration of breastfeeding, the time when the mother seroconverted, and the presence of 
some clinical diseases. In Malawi and Tanzania, prolonged breastfeeding for about 2 years has 
been shown to increase the cumulative risk of HIV MTCT to as high as 15%.88,89 A meta-
analysis comparing rates of infection between infants of women who seroconverted postnatally 
versus infants of women whose HIV-infection was confirmed during delivery, infants whose 
mothers seroconverted postnatally had a higher risk of acquiring HIV (Risk = 29%; 95% CI: 16 - 
24%) compared to the risk for infants whose mothers’ HIV-infections were confirmed at delivery 
(Risk = 14%; 95% CI: 7 - 22%).85 Similarly, a prospective study of HIV-infected mothers who 
were either HIV-seropositive at delivery and whose infant tested HIV negative at six weeks (HIV 
exposed) or HIV-seronegative at delivery and whose infant also tested HIV-negative at six 
weeks showed that the breastfeeding-associated risk of HIV transmission was 2.9 times as high 
among women who seroconverted postnatally compared to women who were HIV-seropositive 
at baseline (delivery).90 The occurrence of clinical diseases such maternal mastitis and nipple 
lesions during breastfeeding also increases the risk of vertical HIV transmission.66,91,92 
 
Prevention of HIV mother-to-child transmission  
PMTCT has been a dynamic and rapidly changing field. Since the early days of the HIV 
epidemic, several interventions have been tried to prevent the vertical transmission of HIV. 
These interventions included washing the birth canal,93 antenatal supplementation with vitamin 
A,94 and treatment of chorioamnionitis.95 Although these interventions had maternal and child 
health benefits, and were quick to implement in poor countries due to low cost, they lacked 
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efficacy in reducing HIV MTCT.96 Since antiretroviral prophylactic drugs were shown to be 
effective in reducing HIV MTCT in the developed world,97 a lot of effort has been made to ensure 
that the drugs are available to all HIV-infected pregnant and breastfeeding women worldwide.  
WHO issued the first recommendations for the use of ARV drugs for PMTCT in 2000 98 to 
harmonize the implementation of PMTCT programs. Over time, these recommendations have 
been revised 99-102 as simplified and standardized regimens, and more potent ARV prophylaxis 
regimens, have become available. The changes were also necessitated by the availability of 
evidence on the effectiveness of ARVs in preventing MTCT, safety of ARV drugs for pregnant 
women, and drug resistance following ARV prophylaxis among pregnant women and its 
implications for future treatment options.  
 
Treatment options for PMTCT programs 
Currently, WHO lists three options for PMTCT: Option A, Option B and Option B+.8 Both 
Options A and B recommend triple ARVs for HIV-infected women with CD4 cell count < 350 
cells per mm3, and prophylaxis for HIV-infected pregnant women with CD4 cell count ≥ 350 cells 
per mm3 as early as 14 weeks of gestation. For women with CD4 cell count ≥ 350 cells per 
mm3, Option B uses triple ARVs as prophylaxis for women with CD4 ≥ 350 cells per mm3 
throughout antepartum and to 1 weeks after breastfeeding cessation (for those breastfeeding).  
Under Option A, pregnant women with CD4 cell count ≥ 350 cells per mm3 use azidothymidine 
(AZT) throughout antepartum, single dose nevirapine (sdNVP) plus first dose of azidothymidine 
/ lamivudine (AZT/3TC) during labor, and daily AZT/3TC through 7 days of postpartum. Option 
B+ recommends offering lifelong triple ART to all confirmed HIV-infected pregnant or 
breastfeeding women regardless of their WHO clinical stage or CD4 cell count. Option B and 
Option B+ ensure that HIV-infected pregnant women receive fully suppressive triple ART 
regimen during pregnancy.  While treatment for infants born to HIV-infected women depends on 
infant feeding method (daily nevirapine (NVP) until 1 week after cessation of breastfeeding or 
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daily NVP through age 4-6 weeks if not breastfeeding) under Option A, both Option B and 
Option B+ recommends infants to receive daily NVP or AZT from birth through age 4-6 weeks 
regardless of infant feeding method .11,102 
 
Benefits of Option B+ over Option A and Option B 
Besides preventing mother-to-child HIV transmission, the Option B+ approach has the 
potential to improve the operations of PMTCT programs, improve maternal health beyond 
pregnancy, and reduce HIV transmission from HIV-infected women to their sexual partners.5,102  
 HIV pregnant women need to receive a fully suppressive triple ARV regimen so that the 
risk of infant infection is minimized and their own health benefit is maximized during pregnancy. 
However, linking PMTCT program access to CD4 cell count testing to determine eligibility has 
been a major challenge for increasing uptake of PMTCT programs in resource-constrained 
settings.5 The Option B+ strategy offers an escape from the CD4 cell count testing requirement 
for determining treatment eligibility under Option A and Option B. This break in the link between 
PMTCT and CD4 cell count testing under Option B+ has simplified the PMTCT program 
requirements and increased ART uptake during pregnancy. Additionally, under Option B+, all 
women continue ART after breastfeeding cessation, whereas under Option B, only those 
women with CD4 counts below treatment eligibility thresholds continue ART. 
 In sub-Saharan Africa, almost 60% of the region’s HIV infections are among 
reproductive-aged women (ages 15-49 years).55  These relatively young HIV-infected women 
are likely to get pregnant at least once, and in some countries, the pregnancy rate among HIV-
infected women is comparable to the general population.103 Among the HIV-infected women, the 
incidence of pregnancy ranges from 9 to 24.6 pregnancies per 100 person-years. Furthermore, 
HIV-infected women on ART are more likely to get pregnant than HIV-infected women not on 
ART.103-105  Since Option B+ extends treatment beyond pregnancy and breastfeeding, it has the 
potential to protect the next pregnancy from HIV from its inception. Option B+ also avoids the 
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risks associated with stopping and re-starting triple ART among reproductive-aged women. 
Continuing on ART treatment beyond pregnancy and breastfeeding may improve maternal and 
child health by reducing the risk of opportunistic infections and deaths due to interrupted ART. 
  HIV viral load is one of the most important determinants of the risk of HIV transmission. 
Among heterosexual men and women in a community-based study in a rural district in Uganda, 
an adjusted seroconversion rate ratio of 2.45 (95% CI: 1.85 - 3.26) was associated with each 
log increment in the viral load.106 ART has been shown to reduce HIV-1 concentration to 
undetectable level in the plasma,107,108 semen 109,110 and cervicovaginal108  among people 
receiving ART. As a result of the decline in HIV-1 concentrations, ART had been proven to 
prevent mother-to-child transmission97,111 and reduce HIV transmission among adults in 
ecological studies, observational cohort studies and randomized clinical trials. A reduction in 
HIV transmission among serodiscordant couples has been shown in systematic reviews and 
meta-analyses of observational studies comparing sexually engaged serodiscordant couples 
receiving ART with those not receiving ART.112,113 The HPTN 052 study, a randomized clinical 
trial of HIV serodiscordant partners, showed that counselling and earlier initiation of ART 
reduced linked HIV transmissions by 96.4%.114  
A number of mathematical models have been developed to assess the impact of 
treatment as prevention on generalized epidemics. In a systematic comparison of 12 models 
that were developed to evaluate a set of standardized ART intervention scenarios in South 
Africa, all models suggested that ART, at high levels of access and with high adherence, has 
the potential to substantially reduce new HIV infections.115 An interesting finding from one of the 
models that was included in the comparison is that universal voluntary HIV testing with 
immediate ART as a strategy would lead to an HIV elimination phase within 5 years.116 
Realizing the potential impact of treatment as prevention, WHO issued 
recommendations on the strategic use of antiretrovirals to help end the HIV epidemic that 
encourages countries to consider expanding ART to subpopulations that include pregnant 
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women and serodiscordant couples regardless of CD4 cell count.117 These guidelines have 
been continually revised to recommend ART initiation at earlier infection stages as evidence for 
the clinical and prevention benefits of early treatment has mounted. The recommendations aim 
at ensuring that ART is not only having health benefits but also prevention impact. Although the 
main purpose of Option B+ is for PMTCT, Option B+ also has the potential for continued 
prevention of sexual HIV transmission in serodiscordant couples or partners by extending ART 
beyond pregnancy and breastfeeding. However, the impact of Option B+ on the HIV epidemic 
through reduced heterosexual transmission has not been quantified in Malawi, the first country 
to implement this strategy.  
 
Optimal timing for ART initiation during pregnancy  
 The effect of ART exposure during pregnancy on fetal development is still unclear. In 
studies comparing adverse birth outcomes between infants exposed to ART and those not 
exposed to ART during pregnancy, some have shown an increased risk of preterm birth, LBW 
or stillbirths among those exposed to ART,118-122  while others have shown no difference123 or 
improved outcomes.124 The timing of ART initiation for pregnant women may also have 
implications for the development of the fetus. In a cohort study comparing preterm delivery and 
LBW between women who used ART pre-conception and those who initiated ART during 
pregnancy,  ART used in pre-conception was associated with an increased risk for preterm 
births and LBW.125,126 For infants who were exposed to ART during pregnancy, early exposure 
(exposed <28 weeks gestation) was associated with an increased risk of preterm birth 
compared to late exposure (exposed ≥28 weeks).118  
While these findings show that there is some risk associated with early ART exposure 
during pregnancy on birth outcomes, the results are not conclusive. These findings do not 
elucidate the optimal time to initiate ART among HIV-infected pregnant women in order to 
minimize adverse pregnancy outcomes. Since there is also evidence that early exposure to ART 
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during pregnancy is associated with reduction in HIV MTCT,127,128 there is a need to determine 
an optimal time to initiate ART among pregnant women that will be effective in maximizing 
reduction in transmission while minimizing adverse birth outcomes. 
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CHAPTER THREE: RESEARCH DESIGN AND METHODS 
Aim 1: Time of ART initiation and preterm birth 
Study Design 
To estimate the association between time of ART initiation during pregnancy and risk of 
preterm birth, we conducted a retrospective cohort study among HIV-infected pregnant women 
delivering a singleton live birth at Bwaila Hospital in Lilongwe, Malawi from April 1, 2012 through 
November 15, 2015. The data we used were collected and entered into a Point-of-Care 
Electronic Medical Records System (POC-EMRS) database at the time of delivery.  
 
Study population 
In Malawi, pregnant women attending antenatal clinics undergo HIV counselling and 
rapid HIV testing using the opt-out approach:129 an HIV test is performed after notifying the 
pregnant woman that the test is routinely performed, but that she may elect to decline or defer 
testing.  All pregnant women who test for HIV are asked to provide locator information to be 
used for contact in the event of abnormal test results. Until July 2011, all confirmed HIV-infected 
pregnant women were required to undergo CD4 count testing to determine if they were eligible 
for ART.  Based on WHO recommendation for HIV-infected pregnant women, pregnant women 
with CD4 <350 or WHO Clinical Stage 3 or 4 were eligible to start ART. HIV-infected pregnant 
women with CD4 counts ≥350 cells received single dose nevirapine (NVP) for PMTCT under 
“Option A” or a combination regimen under “Option B”. Since the adoption of Option B+ in July 
2011, confirmed HIV-infected pregnant women are no longer required to undergo CD4 cell 
count testing to determine if they are eligible for ART. HIV-infected pregnant women are initiated 
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on ART for life regardless of CD4 cell count or WHO clinical stage as soon as they are 
diagnosed. As our study was conducted in the “Option B+ era,” all pregnant women in the study 
population were eligible for lifelong ART.   
To limit confounding due to the intrinsic link between length of gestation and ART 
duration during pregnancy, we constructed our study population such that the risk period for the 
outcome (preterm birth) was entirely separate from the eligible ART start times. Specifically, we 
restricted our analysis to women who: a) delivered on or after 27 weeks of gestation, and b) 
either started ART before 27 weeks or did not receive ART at all prior to delivery.  Additional 
details about this approach are included in Chapter 4.   
. 
Exposure Assessment 
HIV-infected women in the cohort were classified according to their ART exposure status 
at the time of delivery. For women who were on ART at delivery, we further classified them 
based on the time that they started ART: 1) before pregnancy (on ART at conception), 2) during 
the 1st trimester, or 3) during the 2nd trimester (<27 weeks of gestation).  
 
Outcome assessment 
Preterm births were identified based on the reported date of last menstrual period (LMP) 
and date of delivery. We classified a newborn baby as preterm if the baby was born alive and 
the birth occurred at or after 27 weeks of gestation and before 37 weeks of gestation (27 -  < 37 
weeks). Births occurring at 37+ weeks were considered full term. 
 
Covariates assessment  
We used a directed acyclic graph (DAG) to identify a minimally sufficient set of 
covariates to include in our analysis. All covariates that were collected and recorded in the 
maternity database during delivery were considered for inclusion in the DAG, with selection 
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further based on literature review and biological plausibility. The variables that were recorded 
included maternal age, education, gravidity, parity, and mode of delivery (spontaneous vaginal, 
vacuum extraction, breach, and caesarean section). Parity was preferred over gravidity for 
consideration as a confounder based on literature review. 
After identifying the minimally sufficient set of potential confounders (mother’s age, 
education and parity), we explored the best way of modeling continuous variables so that they fit 
the data well. Polynomials were used to assess linearity of continuous variables. To check for a 
linear trend in the response, we divided the continuous variables into categories based on 
scientific knowledge or literature review. For a more flexible assessment of the functional form 
of the continuous independent variables, we used both linear and quadratic spline models. 
Linear spline models allow the slope of the dose-response to change at each knot, while 
quadratic spline models allow the shape and direction of the dose-response curve to change at 
each knot. Goodness of fit for polynomial and spline models was assessed using likelihood ratio 
test (LRT). Based on this process, we included maternal age as a linear term in our model, and 
parity as ordinal. 
 
Statistical analyses 
Descriptive Analysis 
Descriptive data analysis was used to assess variable distributions and detect outliers or 
influential observations. We estimated means (and standard deviations) and medians (and 
interquartile ranges) of continuous variables, and proportions of categorical variables. In 
addition, we examined the distributions of continuous variables using boxplots, histograms and 
scatterplots.  
We also assessed the frequency of missing values for all variables including the main 
exposure and outcome. All observations with missing main exposure or outcome were excluded 
from the analysis. Mother’s education was missing from 95% of records, and was thus excluded 
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from the analysis despite being among our minimum set of covariates identified through the 
DAG. All continuous and ordinal explanatory variables were assessed for collinearity using 
correlation coefficients. A correlation coefficient ≥ 0.5 was considered indicative of a strong 
correlation.  
Fisher exact tests were used to asses differences in the distribution of categorical 
covariates between the outcome categories (preterm or full term) as well as across the 
exposure categories (ART initiation: before pregnancy, 1st trimester, 2nd trimester, or never 
initiated). T-test and one-way analysis of variance (ANOVA) was used to test differences in 
means between the outcome categories and across the exposure categories respectively.  
 
Multivariable analysis 
To estimate the association between ART use and preterm birth, and between time of 
ART initiation and preterm birth, we used log-binomial regression to calculate both unadjusted 
and adjusted risk ratios and the corresponding 95% confidence limits. Using log-binomial 
regression allowed us to take into account the effect of confounders on the relationship between 
ART exposure and risk of preterm birth. 
The risk ratio (RR) is the cumulative incidence (𝐶𝐼𝐸) of the outcome (D+) among the 
exposed (E+), divided by the cumulative incidence (𝐶𝐼𝐸−) of the outcome (D+) among the 
unexposed (E-), for a fixed period of time. 
 
𝑅𝑅 =  
𝐶𝐼𝐸 
𝐶𝐼𝐸− 
     (1) 
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Log-binomial regression assumes a linear relationship between the risk ratio and the 
covariates on the log scale and can be expressed follows:  
 
𝑙𝑜𝑔[ 𝑅𝑅 | (𝑋, 𝒁) ] =  𝛼 + 𝛽𝑋 + 𝛾𝒁         (2) 
 
 where 𝑋  is the exposure and 𝒁  is the covariate vector.  Taking the exponent of equation (2), 
the RR can be expressed as:  
 
𝑅𝑅|(𝑋, 𝒁)  = 𝑒𝑥𝑝(𝛼 + 𝛽𝑋 + 𝛾𝒁)         (3) 
 
In the multivariable log-binomial regression model scenario as presented in (2), the 
regression parameter 𝛽  is the log risk ratio for a unit change in exposure variable 𝑋 while 
holding the covariates vector 𝒁 constant at any level of 𝒛  (not necessarily the same level for all  
𝐳 covariates). The exponent of  𝛽 as in (3) is the risk ratio for a unit change in exposure variable 
𝑋 while holding the covariate vector 𝒁 constant at any level of 𝒛 . 
Potential confounders identified through the DAG analysis were first assessed for effect 
measure modification (EMM) using a LRT with an a priori p-value of > 0.15. A full model with all 
of the covariates (including interaction terms) was compared to a reduced model containing all 
of the covariates in the full model except the interaction terms being assessed. Interaction terms 
resulting in LRT with p-value < 0.15 were retained in the model. None of the potential 
confounders were considered as EMM based on this criterion. 
Finally, we evaluated the necessity of including the potential confounders in the 
multivariable model using the change-in-estimate approach. The change-in-estimate of the 
ln(RR) for preterm birth was calculated by comparing the absolute difference in the value  of 
ln(RR) between a full model with all the covariates included and a reduced model with the 
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potential confounder being assessed excluded. The absolute difference was calculated as 
follows: 
 
|𝑙𝑛(𝑐𝑜𝑅𝑅)| =  |
𝑙𝑛(𝑅𝑅𝑤𝑖𝑡ℎ 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠)
𝑙𝑛(𝑅𝑅𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠)
|  
where coRR is the confounding risk ratio. As specified a priori, a potential confounder that 
resulted in ≥ 10% change in the estimate of ln(RR) after being excluded from the model was 
considered a strong confounder. Both mother’s age and parity were retained in the model as 
strong confounders.  
 
Sub analyses 
The definition that we used for preterm, baby born alive and the birth occurred at or after 
27 weeks of gestation but before 37 weeks of gestation, includes extremely preterm (< 28 
weeks), very preterm (28 to < 32 weeks), moderate preterm (32 to < 34 weeks), and late 
preterm infants (34 to < 37 weeks).  In order to assess the effect of time of ART initiation on 
each of these preterm gestational categories, we carried out three additional analyses. In the 
first model, we compared extremely to very preterm births with term births, excluding moderate 
to late preterm births. Second, we compared moderate to late preterm births with term births, 
excluding extremely preterm to very preterm births. In the third model, we compared extremely 
preterm to moderate preterm births (< 34 weeks) with late preterm to term births (≥ 34 weeks).  
All statistical analyses were performed using SAS software, version 9.4 (SAS Institute 
Inc., Cary, NC). 
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Aim 2: Option B+ and female-to-male HIV transmission 
 
Study design 
To estimate the expected relative reduction in HIV incidence among men over time 
under Option B+ compared to Option B, we used a deterministic, compartmental mathematical 
model to capture the population dynamics of women under the two PMTCT strategies. We then 
calculated HIV transmission under each strategy as a function of the numbers and relative 
infectiousness of HIV-infected women according to disease stage, ART status, and pregnancy 
status.   
 
Study population 
The model was based on the sexually active female population aged 15 – 49 years old 
in Lilongwe, Malawi. Malawi, one of the countries in sub-Saharan Africa with a high prevalence 
of HIV, has a population of 13.1 million (6.4 million males and 6.7 million females).130 The HIV 
pandemic in Malawi has disproportionately affected women. In 2010, the prevalence of HIV was 
estimated to be higher among women (12.9%) than men (8.1%).131  Besides heterosexual 
contact, vertical transmission of HIV to children who have been exposed to HIV during 
pregnancy or breastfeeding is also common. 
We chose this study population because the main HIV transmission mode in Malawi is 
through heterosexual contact. In addition, Malawi was the first country to start implementing the 
PMTCT Option B+ program for all confirmed HIV-infected pregnant and breastfeeding women.  
 
Model structure 
We developed a deterministic, compartmental model to capture the population dynamics 
of women only. The model was stratified into compartments according to HIV status (HIV-
uninfected, HIV-infected), age cohorts (15-19, 20-24, 25-34 and 35-49), and pregnancy / 
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breastfeeding status (not pregnant / breastfeeding, pregnant / breastfeeding). HIV infected 
women were further stratified by HIV disease stage based on CD4 cell count (CD4 ≥500, 350 ≤ 
CD4 ≤499, 200 ≤ CD4 ≤349, and CD4 < 200) and ART status (ART naïve, on ART, and ART 
drop-outs). Model equations are given in Appendix 1. 
 
Population dynamics among women 
Young women aged into the 15-19 years age group as HIV susceptible and without prior 
pregnancy. After entering into the model population, women could become infected with HIV, 
become pregnant, and age into the next older age category. HIV-infected women (pregnant or 
not) progressed through CD4 stages and could start ART treatment depending on the prevailing 
Malawi government guidelines for ART eligibility. Both HIV-negative and HIV-infected women 
were removed from the population through aging out of the sexually active population upon 
reaching 50 years of age. In addition, HIV-infected women were removed from the population 
through death from AIDS. 
 
HIV infection and progression among women 
HIV-uninfected women became infected at an age- and calendar-time-specific infection 
rate that further depended on pregnancy and breastfeeding status. Following infection, 
individuals entered into one of the four HIV disease stages according to observed proportions of 
infected persons who progress directly from primary infection to each stage. Untreated HIV 
progression occurred from one stage to the next: early asymptomatic stage without significant 
immunosuppression (CD4 ≥500) to late asymptomatic stage with mild immunosuppression (350 
≤ CD4 ≤499), to early AIDS with advanced immunosuppression (200 ≤ CD4 ≤349), and finally to 
full-blown AIDS with severe immunosuppression (CD4 < 200). HIV-infected women not on ART 
progressed from one CD4 cell count strata to the next at a rate that was reciprocal to the time 
expected to be spent in each CD4 strata. Women on ART were assumed to have a slower 
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progression rate compared to women who were not on ART.  Women who dropped out of ART 
were assumed to progress to the next CD4 cell count stratum at the same rate as women who 
had never initiated ART. 
 
Pregnancy and breastfeeding 
Women became pregnant at age- and calendar-time-specific fertility rates that depended 
on women’s HIV status, and ART status for HIV-infected women. The number of either pregnant 
or breastfeeding women at a particular time varied according to these fertility rates and the 
expected duration of pregnancy and breastfeeding. We assumed that women in both Option B 
and Option B+ breastfed their babies for the same fixed period of time.   
 
ART uptake, retention and drop-out 
ART uptake depended on ANC attendance rates (for either pregnant or breastfeeding 
women), ART eligibility under Malawi government guidelines in a given calendar year, and 
estimated ART uptake by eligible women. A small proportion of women could drop out of the 
ART program each year. According to common practice, and given a lack of empirical 
information about ART re-initiation according to disease stage, we assumed that drop-outs did 
not re-initiate ART unless they entered the final HIV stage (at which point they would be ill 
enough to hasten treatment re-initiation) or became pregnant and eligible for PMTCT. Once 
eligible for re-initiation, ART drop-outs re-initiated ART at the same rate that ART naïve persons 
initiated ART.  
 
HIV transmission from women to men  
The model specified a time-varying function (the net transmission rate) describing HIV 
transmission from women to men. Transmission was a function of the numbers of HIV-infected 
women in each model compartment at a given time, along with the relative infectiousness 
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associated with disease stage, ART status, and pregnancy status. Infectiousness among 
asymptomatic, not on ART, and not pregnant women served as the referent.  
 
Model Analysis 
All model analyses were done in R software, version 3.2.0. The differential equations 
were coded in deSolve,132 a package in R that solves initial value problems (IVP) of ordinary 
differential equations (ODE), differential algebraic equations (DAE), partial differential equations 
(PDE) and delay differential equations (DeDE).  
The model equations were specified in an R function describing the rate of change of the 
number of individuals in each compartment (state variables) as a function of input parameters 
and the time-varying numbers of individuals in the compartment. Input to the function included 
the initial values for the compartments, prior distributions on input parameters (transition rates), 
and the length of time for running the model.  
The output from the system of differential equations was the number of women in each 
compartment over time. We used the output from the model to estimate and compare the net 
transmission rate for female-to-male transmission under Option B+ and Option B.  
 
Model fitting 
We used a Bayesian melding approach to fit our model to estimated ART coverage, 
estimated population-level HIV prevalence, and sentinel surveillance estimates of HIV 
prevalence from antenatal clinics in Lilongwe, Malawi. First, we ran 100,000 simulations using 
input parameter values sampled from the parameters’ prior distributions, with each run resulting 
in a unique epidemic curve.  Next, we filtered out curves in which output values for recent ART 
coverage and overall HIV prevalence were deemed implausible. The remaining curves were 
then assigned weights based on the likelihood of observing the ANC surveillance estimates for 
a given set of input parameters in our model. We then resampled (with replacement) the 
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epidemic curves, with the probability of resampling being proportional to the likelihood-based 
weight that was assigned to the curve.  Finally, based on the resampled curves, we estimated 
the best posterior trajectory of the output (the median) with the corresponding 95% credible 
limits calculated as the lower 2.5th and the upper 97.5th percentiles of the output at each time 
point.  
 
Comparing PMTCT strategies’ impact on female-to-male transmission  
After completing the Bayesian melding process, we ran three model scenarios to 
compare the effect of Option B+ with Option B on female-to-male transmission since Option B+ 
started (2011) and projected to 2020. In the first scenario, we assumed that Option B+ was the 
PMTCT strategy and used observed ART-for-PMTCT and ART-for-Health uptake up to 2014. 
From 2014 to 2020, we held the values of ART-for-PMTCT and ART-for-Health at the 2014 
levels. In the second scenario, we assumed that Option B was the PMTCT strategy, with ART 
uptake values in the period 2011-2020 assumed to be the same as those assumed for Option 
B+; the only difference being ART discontinuation following breastfeeding cessation. In the third 
scenario, we also assumed that Option B was the PMTCT strategy, but we assumed that ART 
uptake values in the period 2011-2020 remained at 2011 levels; the differences in comparison 
to Option B+ were different ART uptake rates and ART discontinuation following breastfeeding 
cessation. In all three scenarios, all other parameters were fixed at 2011 values.  We calculated 
the net transmission rate over time in each of the three scenarios and compared the Option B+ 
results to each of the Option B scenarios to assess the impact of Option B+ on heterosexual 
transmission between 2011 and 2020.  
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CHAPTER FOUR: THE RELATIONSHIP BETWEEN MATERNAL ANTIRETROVIRAL  
THERAPY INITIATION TIME AND PRETERM BIRTH: OPTION B+ FOR THE 
PREVENTION OF MOTHER-TO-CHILD HIV TRANSMISSION IN MALAWI 
 
Introduction 
Preterm birth, often defined as birth before 37 weeks of gestation,27  is the second-
leading cause of death in children under five years,24  and accounts for 75% of all perinatal 
mortality worldwide.25,26 Of the estimated 15 million infants born preterm in 2010, more than one 
million died as a result of prematurity.24-27 In sub-Saharan Africa, about 12% of live births are 
preterm, with Malawi registering the highest preterm birth prevalence worldwide (18%).23  
HIV is also endemic in sub-Saharan Africa, with 59% of all prevalent HIV infections 
occurring among women.133 Prevention of mother-to-child HIV transmission (PMTCT) is thus a 
major public health priority.  Antiretroviral therapy (ART) for HIV-infected women during 
pregnancy can virtually eliminate the risk of vertical HIV transmission,1,4,134 with the additional, 
important benefit of reduced maternal morbidity and mortality.9,135-137  
In July 2011, Malawi became the first country to adopt a strategy of universal life-long 
ART for pregnant and breastfeeding women regardless of HIV disease stage or CD4 count.5 
The scale-up of this approach, called “Option B+”, is expected to help bring an end to new 
pediatric HIV infections and substantially improve maternal health in settings with high HIV 
burdens.101 Since the introduction of PMTCT Option B+ in Malawi, the number of pregnant or 
breastfeeding women on ART has increased dramatically,6 and in 2013 the World Health 
Organization (WHO) recommended it for all countries with a generalized HIV epidemic.8  
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Despite the clear benefits of Option B+ for maternal health and the prevention of vertical 
HIV transmission, the effects of ART exposure during pregnancy on fetal development and birth 
outcomes are still unclear.118-124 In particular, few studies have examined the relationship 
between the timing of maternal ART initiation and preterm delivery.118,125,126 In this study, we 
used data from the maternity unit of a large, urban hospital in Malawi to estimate the risk of 
preterm births among HIV-infected women according to maternal ART status and time of ART 
initiation in the Option B+ era.  
 
Methods 
Study design, setting, and population 
We conducted a retrospective cohort study using data collected at delivery from HIV-
infected pregnant women delivering a singleton live birth at Bwaila Hospital in Lilongwe, Malawi 
from April 1, 2012 through November 15, 2015. The data for analysis were obtained from a 
point-of-care electronic medical record system (POC-EMRS) developed by Baobab Health Trust 
and hosted at the hospital. All records in the database of the POC-EMRS were entered directly 
by a health care worker while examining the mother at the time of delivery. Information about 
HIV status and ART (for HIV-infected women) was cross-checked with documentation in the 
mother’s personal health passport, a government-issued document that contains information on 
general history, diagnoses, treatments, antenatal consultations, and deliveries. 
ART duration during pregnancy is intrinsically linked to length of gestation (and thus 
preterm birth): women initiating ART later in pregnancy are necessarily closer to reaching term, 
and are therefore less likely to experience preterm birth. In an attempt to remove this potentially 
confounding relationship from our analysis, we constructed our study population such that the 
risk period for the outcome (preterm birth) was entirely separate from the eligible ART start 
times. Specifically, we restricted our analysis to women who: a) delivered on or after 27 weeks 
of gestation, and b) either started ART before 27 weeks or did not receive ART at all prior to 
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delivery (Figure 4.1). In other words, we chose a cut-off of 27 weeks to define the start of the 
risk period for preterm birth. This start point is at the upper end of values (which range from 20 
to 28 weeks) that have been used in other settings;27 this choice allowed us to minimize the 
number of women initiating ART during pregnancy that we would need to exclude in order to 
keep ART start times separate from the preterm risk period .  Women with missing information 
on the main exposure (ART use) were also excluded.  
This study was approved by the National Health Sciences Research Committee 
(NHSRC) of Malawi and the Institutional Review Board (IRB) at the University of North Carolina, 
Chapel Hill. 
 
Variable definitions and classifications 
HIV Status:  Each woman’s HIV status was determined at the time of admission to the 
maternity unit.  Women whose health passports indicated prior HIV-positive test results were 
considered to be HIV-infected at the time of delivery; women without health passport 
documentation of HIV-positive status underwent HIV testing at the time of delivery to determine 
HIV infection status. Women found to be HIV-infected based on either the health passport or 
testing at delivery were recorded as such in the database and were eligible for inclusion in the 
study.     
Main outcome – preterm birth:  Preterm birth status was based on gestational age at 
delivery, which was calculated as the difference between date of delivery and the reported date 
of last menstrual period (LMP) recorded in the health passport during the first antenatal visit. We 
defined preterm birth as birth on or after 27 weeks of gestation and before 37 weeks of 
gestation.  Births occurring at 37+ weeks of gestation were considered full term.27   
Main exposure – ART:  ART status and timing of ART initiation were determined at 
delivery according to maternal interview and information recorded in the health passport in the 
course of routine antenatal care.  Eligible HIV-infected women with no history of ART use were 
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considered to be unexposed to ART for the purposes of this analysis, even if short-course ART 
was received at the time of delivery. These women comprised the “not on ART before delivery” 
group.  Women whose health passports indicated ART initiation at or after 27 weeks of 
gestation were excluded from the analysis, as their ART exposure began after the start of the 
risk period for preterm birth. The remaining ART-exposed women were assigned to one of three 
categories according to timing of ART initiation: 1) before pregnancy (on ART at conception), 2) 
during the 1st trimester, or 3) during the 2nd trimester (specifically, the portion of the 2nd trimester 
<27 weeks).  
 
Confounders  
Using a directed acyclic graph (DAG)138,139 containing variables in the database, we 
identified mother’s education, age, and parity as potential confounders for inclusion in the 
analysis. Based on the functional form of the relationship between each confounder and 
outcome, we modeled mother’s age as continuous and parity as ordinal.  We used a manual, 
backward elimination, change-in-estimate strategy at a 10% retention threshold to assess the 
necessity of including each confounder in the final model.140 We were unable to assess 
education as a confounder, as values for this variable were missing from 95% of records.   
 
Statistical Analyses 
We used Fisher exact tests to test differences in proportions between groups, and t-tests 
and one-way analysis of variance (ANOVA) to test differences in means as appropriate. We 
used log-binomial regression models to estimate unadjusted and adjusted risk ratios (uRRs and 
aRRs, respectively) and 95% confidence intervals (CI) of the association between ART 
exposure category and preterm birth, with those who did not initiate ART prior to delivery 
serving as the referent category.  
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In sub-analyses, we considered three preterm birth sub-categories: extremely to very 
preterm (27 to < 32 weeks), moderate preterm (32 to < 34 weeks), and late preterm (34 to <37 
weeks).27  In the first sub-analysis, we treated extremely to very preterm births (versus not 
preterm) as the outcome, excluding moderate to late preterm births from the analysis.  In a 
second sub-analysis, we treated moderate to late preterm births (again versus not preterm) as 
the outcome, this time excluding extremely to very preterm births. In a third sub-analysis, we 
dichotomized the outcome as <34 weeks versus ≥34 weeks (extremely to moderate preterm vs. 
late preterm or full term), because births prior to 34 weeks’ gestational age require advanced 
neonatal support, and their relationship with ART status and initiation time is thus of high clinical 
interest in this setting. 
All statistical analyses were performed using SAS software, version 9.4 (SAS Institute 
Inc., Cary, NC). 
 
Results 
Among 66,029 women who delivered in the maternity ward at Bwaila Hospital during the 
study period, 6,853 women (10.4%) were known to be HIV-infected. Of the HIV-infected women, 
4,988 (72.8%) had singleton live births at 27+ weeks of gestation and were thus eligible for our 
study. After excluding women with missing ART initiation time and those who initiated ART at or 
after 27 weeks, 3,074 women were included in the analyses (Figure 4.2). Most women had 
initiated ART before pregnancy (N=1139, 37.0%) or during the second trimester (N=1503, 
48.9%).  Only 5.4% had not initiated ART prior to delivery (N=165), including three women who 
received ART at the time of delivery only. 
On average, women who had never initiated ART prior to delivery were younger than 
those who had received ART during pregnancy, and age at delivery increased with earlier ART 
initiation times (p < 0.001) (Table 4.1). The distribution of parity was different across the ART 
exposure categories (p < 0.001), and mean gestational age at delivery was similar between 
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those who never initiated ART and those who were on ART, regardless of the time of ART 
initiation (p = 0.05) (Table 4.1). A total of 731 preterm births were observed during the study 
period (risk = 24%; 95% CI: 22% - 25%).Women who delivered preterm babies were on 
average younger than those who delivered full term babies (mean age = 27.6 vs 28.4, p < 
0.001) (Table 4.1).   
In the main analysis, the risk of preterm birth was similar in women who had initiated 
ART at any point prior to delivery compared to those who never initiated ART (aRR = 0.88; 95% 
CI: 0.65 – 1.19) (Table 4.2). There was not a clear trend in the relationship between timing of 
ART initiation and risk of preterm birth.  Compared to women who had not initiated ART prior to 
delivery, the aRRs for preterm birth were 0.78 (95% CI: 0.57 – 1.08), 1.03 (95% CI: 0.72 – 
1.49), and 0.92 (95% CI: 0.67 – 1.25) for initiating ART before pregnancy, during the 1st 
trimester, and during the 2nd trimester, respectively, after adjustment for mother’s age and 
parity.  
In sub-analyses focusing on extremely to very preterm birth vs. full term birth, we found 
ART initiation at any point before delivery to be strongly protective (aRR = 0.43; 95% CI: 0.26 – 
0.72) (Table 4.3).  Separate consideration of ART initiation before pregnancy (aRR = 0.42; 95% 
CI: 0.24 – 0.73), in the 1st trimester (aRR = 0.54; 95%CI: 0.27 – 1.10), and in the 2nd trimester 
(aRR = 0.42; 95% CI: 0.24 – 0.72) suggested that all three initiation times were protective 
against extremely to very preterm birth.  
There was some evidence of an increased risk of moderate to late preterm (vs. full term) 
births associated with ART use prior to delivery (aRR = 1.16; 95% CI: 0.75 – 1.80) (Table 3). In 
particular, initiation in the 1st or 2nd trimester (vs. no ART before delivery) was associated with 
higher risk of moderate to late preterm birth, but these estimates were imprecise. ART initiation 
prior to pregnancy was not associated with moderate to late preterm birth.  
Finally, we found ART use prior to delivery to be suggestive of a protective effect against 
birth at less than 34 weeks’ gestation overall (aRR = 0.70; 95% CI: 0.42 – 1.17) (Table 3).  The 
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point estimates for each of the three start times (before pregnancy, during the 1st trimester, 
during the 2nd trimester) were also suggestive of protective effects against birth prior to 34 
weeks.  
 
Discussion 
In this study of birth outcomes among infants born to HIV-infected mothers in Malawi 
since the start of Option B+, we did not find a strong association between ART initiation prior to 
delivery and preterm birth overall.  Importantly, though, we found ART prior to delivery to be 
quite strongly associated with a reduced risk of extremely to very preterm birth (birth between 
27 and 32 weeks of gestation), and moderately associated with a reduction in preterm birth prior 
to 34 weeks.  These results are encouraging because mortality increases as gestational age 
decreases, with only 30% of babies born between 28 and 32 weeks in low-income countries 
surviving.27  In general, ART initiation prior to conception was associated with better outcomes 
relative to non-use of ART than was initiation during pregnancy.  Taken together, these findings 
suggest that ART during pregnancy does not increase the risk of preterm birth, and that it may 
in fact be protective against severe adverse birth outcomes.    
Our findings are consistent with the results of previous studies that have shown a 
protective effect of earlier maternal ART against preterm birth. A study of predominantly black 
African pregnant women who delivered at a single hospital in London found a decreased odds 
of preterm delivery among women who conceived while receiving ART compared to women 
who received ART following conception.141 Results from a study in Malawi and Mozambique 
showed a protective effect of a longer course of ART during pregnancy against preterm birth, 
although the investigators did not differentiate between those who started ART prior to 
conception and those who started during pregnancy.142  
A small number of previous studies in both developed and developing countries have 
found early ART exposure during pregnancy to be associated with increased risk of preterm 
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birth. In an analysis from abstracted obstetrical records at six sites in Botswana, women who 
started highly active antiretroviral therapy (HAART) prior to pregnancy had a higher odds of 
delivering preterm babies compared to HIV-infected women with no ART exposure and those 
initiating HAART or zidovudine monotherapy during pregnancy.120  Similarly, results from a 
prospective cohort study in Brazil found that starting ART before conception increased the odds 
of preterm birth, although the effect estimate was very imprecise.125 Importantly, both of these 
studies were performed in the era when ART initiation for health and PMTCT was only available 
to those with advanced disease. Advanced maternal HIV is associated with increased risk of 
preterm birth143 and these earlier findings may not be directly applicable to the PMTCT Option 
B+ era when lifelong ART is initiated during pregnancy regardless of HIV disease stage or CD4 
count. 
To our knowledge, our study is the first to provide evidence that ART initiation prior to 
conception is protective against preterm birth in the era of PMTCT Option B+.  As the Option B+ 
program matures and the proportion of women on lifelong ART following a prior pregnancy 
grows, we expect that an increasing proportion of women will be on ART prior to conception. 
Our finding that the risk of preterm was lowest in this group suggests that preterm prevalence 
among HIV-infected mothers is likely to decrease as the time since Option B+ implementation 
increases. Our results also suggest that being on ART during pregnancy is protective against 
extremely to very preterm birth, regardless of time of ART initiation. These findings suggest that 
increased ART uptake in the Option B+ era could have a profound impact on preterm birth and 
neonatal mortality in developing countries where fertility rates are high, HIV is endemic, and 
advanced nursery facilities are not readily available.  
Several mechanisms have been hypothesized for possible adverse effects of ART on 
birth outcomes. Specifically, it has been proposed that protease inhibitor (PI)-based ART could 
induce preterm birth by a cytokine-mediated regulation of the immune system through increased 
Th1 and decreased Th2 cytokines production.144,145  Women with recurrent pregnancy losses 
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have been observed to have increased Th1 and decreased Th2 cytokines.146,147  Compared to 
non-PI-based ART, women on PI-based ART have a higher risk of having preterm birth.120,121 
However, the same cytokine mechanism has been hypothesized to be protective against HIV 
disease progression.148,149 Women who are on established ART before conception may have a 
stabilized cytokine environment due to long exposure to ART, which can be one reason we 
observed ART initiation prior to pregnancy being protective against preterm birth. Additionally, 
the ART regimen used in Malawi, tenofovir / lamivudine / efavirenz (TDF/3TC/EFV), is not PI-
based, which may explain the similar risk of preterm birth  we observed in women who initiated 
ART at any point prior to 27 weeks and those who never initiated ART. 
Studies focusing on the association between duration of ART exposure in utero and 
other fetal outcomes have also suggested that the benefits of earlier ART outweigh the risks. 
Earlier ART initiation during pregnancy was not associated with increased risk of stillbirth or low 
birthweight (LBW) in South Africa (with ART initiation dichotomized at < 28 weeks or ≥ 28 weeks 
of pregnancy),118 or with LBW in United States (with ART initiation dichotomized at ≤ 25 weeks 
or ≥ 32 weeks of gestation).124 A recent cohort analysis in Zambia among infants born at term 
also did not find increased risk of LBW or decreased mean birthweight due to longer duration of 
ART during pregnancy.150   
ART duration during pregnancy is intrinsically linked to length of gestation and thus 
preterm birth. To confine the preterm risk period to an interval in which women were either 
always or never on ART, and to maximize the number of ART initiation intervals (before 
pregnancy, during the 1st trimester, during the 2nd trimester) prior to the start of the risk period 
that we could examine, we restricted our analysis to births that occurred on or after 27 weeks 
and to women who either started ART before 27 weeks or did not receive ART at all prior to 
delivery. We are therefore unable to draw any conclusions about the effects of early ART on 
extremely early preterm birth (prior to 27 weeks) or the effects of ART initiated at or after 27 
weeks on subsequent preterm births.  
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We also note that there may have been some misclassification of preterm status and 
ART initiation time within pregnancy due to inaccurate estimates of the last menstrual period. 
The general consistency of our findings across ART initiation times suggests that such 
misclassification may not be a large concern in our analyses, and our specific finding that 
women initiating ART at any point during pregnancy were less likely to experience extremely to 
very preterm birth (vs. term birth) may be especially robust, given the five-week difference 
between the upper gestational age limit of very preterm (32 weeks) and the lower limit of full 
term (37 weeks).      
Information on several potential confounders was either unavailable or insufficient for 
inclusion in analyses.  In particular, we did not have information on the interrelated covariates of 
ART adherence, CD4 count, and viral load. Poor ART adherence can result in drug 
resistance,151,152 lower CD4, and higher viral loads, leading to adverse maternal and birth 
outcomes. In general, ART adherence is high during pregnancy,153 and we expect that the fixed-
dose TDF/3TC/EFV combination of one tablet per day in our study population would have 
encouraged high adherence in all women receiving ART.5 Furthermore, we would consider viral 
load and CD4 count to be casual intermediates between ART and preterm birth, and thus 
statistical adjustment would have been inappropriate even if viral load and CD4 data had been 
available. We also note that there may have been data entry errors and incomplete data entry, 
but we do not expect such errors or incompleteness to have been differential according to 
exposure or outcome status.  
ART initiation in pregnancy is an indicator of access to prenatal care and other health 
care services. In Malawi, HIV-infected women not on ART are initiated on life-long ART during 
an antenatal care visit,154 in addition to receiving standard prenatal care.  Women who attend 
antenatal care are less likely to deliver low birthweight infants, especially from preterm 
births.155,156 In the likely event that the women who had never initiated ART prior to delivery were 
less likely to have had access to prenatal care, then the higher risk of preterm births among 
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those who did not initiate ART may not be fully attributable to lack of ART during pregnancy. No 
information on dates or numbers of antenatal visits was available in the POC-EMRS to allow 
control for antenatal care receipt in our analyses.  
Nevertheless, our results suggest that the risk of preterm birth – particularly early 
preterm birth – is low among women initiating ART prior to delivery, especially among those 
who initiate ART prior to conception. As the era of PMTCT Option B+ continues, post-weaning 
retention on therapy of women who initiate ART during pregnancy should thus be a priority. 
Additionally, these findings suggest that HIV testing of women who wish to become pregnant, 
followed by ART initiation prior to conception in those testing HIV-positive, could be beneficial. If 
adequate uptake and retention can be achieved, then PMTCT Option B+ may not only 
dramatically reduce vertical HIV transmission and improve maternal health, but also reduce 
preterm birth in settings with heavy, overlapping burdens of HIV and neonatal mortality.   
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Tables and Figures 
Table 4.1. Characteristics of Study Population 
 
 
Characteristics 
Birth Status ART initiation time during pregnancy 
Preterm   
N (%)    
731 (23.8)   
Full Term    
N %)      
2343 (76.2) 
Before pregnancy 
N (%)             
1139 (37.0%)  
1st trimester             
N (%)       
267 (8.7%) 
2nd trimester*       
N (%)             
1503 (48.9%) 
Never initiated                           
N (%)               
165 (5.4%) 
Mother’s age (mean, SD) 27.6 (5.6) 28.4 (5.8) 30.4 (5.4) 27.2 (5.4) 26.9 (5.5) 25.6 (5.5) 
Gestation weeks at delivery   
(mean, SD) 
34.0 (2.2) 39.4 (1.3) 38.3 (2.7) 37.9 (2.9) 38.1 (2.8) 38.0 (3,3) 
Parity       
   Nulliparity 20 (3.3) 46 (2.3) 12 (1.1) 9 (4.1) 40 (3.4) 5 (4.1) 
   Primiparity (1 child) 163 (26.9) 567 (28.6) 239 (22.3) 64 (29.2) 384 (32.7) 43 (35.5) 
   Low Multiparity (2–4  children) 394 (65.0) 1243 (62.8) 739 (68.9) 140 (63.9) 695 (59.2) 63 (52.1) 
   Grand Multiparity (≥ 5 children) 29 (4.8) 124 (6.3) 82 (7.7) 6 (2.7) 55 (6.7) 10 (8.3) 
* before 27 weeks 
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Table 4.2. Associations between ART status and timing of initiation with preterm birth  
 
ART Initiation Status 
Preterm              
N (%)  
Full Term           
N (%)  
Unadjusted RR       
(95% CI)       
Adjusted RR†       
(95% CI) 
731 (23.8)    2343 (76.2)   
On ART  690 (94.4) 2219 (94.7) 0.95 (0.73, 1.25) 0.88 (0.65, 1.19) 
Never Initiated ART 41 (5.6) 124 (5.3) 1.00 1.00 
Before Pregnancy 235 (32.2) 904 (38.6) 0.83 (0.62, 1.11) 0.78 (0.57, 1.08) 
1st Trimester 77 (10.5) 190 (8.1) 1.16 (0.84, 1.61) 1.03 (0.72, 1.49) 
2nd Trimester* 378 (51.7) 1125 (48.0) 1.01 (0.77, 1.34) 0.92 (0.67, 1.25) 
Never Initiated 41 (5.6) 124 (5.3) 1.00 1.00 
†Adjusted for mother’s age and parity 
* before 27 weeks 
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Table 4.3. Associations between ART status and timing of initiation with alternate preterm categorizations   
 
ART Initiation status 
Extremely to Very Preterm*                  
N (%) 
149 (6.0)    
Full Term‡                  
N (%)  
2343 (94) 
Unadjusted RR       
(95% CI)       
Adjusted RR§     
(95% CI) 
On ART  133 (86.3) 2219 (94.7) 0.49 (0.30, 0.81) 0.43 (0.26, 0.72) 
Never Initiated 16 (10.7) 124 (5.3) 1.00 1.00 
Before Pregnancy 50 (33.6) 904 (38.6) 0.46 (0.27, 0.78) 0.42 (0.24, 0.73) 
1st Trimester 14 (9.4) 190 (8.1) 0.60 (0.30, 1.19) 0.54 (0.27, 1.10) 
2nd Trimester** 69 (46.3) 1125 (48.0) 0.51 (0.30, 0.85) 0.42 (0.24, 0.72) 
Never Initiated 16 (10.7) 124 (5.3) 1.00 1.00 
 Moderate to late Preterm† 
N (%)                              
582 (19.9)      
Full Term          
N (%)                 
2343 (81.1) 
  
On ART  557 (95.7) 2219 (94.7) 1.20 (0.83, 1.72) 1.16 (0.75, 1.80) 
Never Initiated 25 (4.3) 124 (5.3) 1.00 1.00 
Before Pregnancy 185 (31.8) 904 (38.6) 1.01 (0.69, 1.48) 1.01 (0.64, 1.11) 
1st Trimester 63 (10.8) 190 (8.1) 1.48 (0.98, 2.25) 1.37 (0.83, 2.25) 
2nd Trimester** 309 (53.1) 1125 (48.0) 1.28 (0.89, 1.86) 1.24 (0.79, 1.93) 
Never Initiated 25 (4.3) 124 (5.3) 1.00 1.00 
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Table 4.3. Associations between ART status and timing of initiation with alternate preterm categorizations (continued) 
                               
ART Initiation Status 
< 34 weeks                         
N (%)                             
243 (7.9) 
≥ 34 weeks       
N (%)            
2831 (92.1) 
Unadjusted RR       
(95% CI)       
Adjusted RR§      
(95% CI) 
On ART  243 (93.4) 2682 (94.7) 0.80 (0.50, 1.30) 0.70 (0.42, 1.17) 
Never Initiated 16 (6.6) 149 (5.3) 1.00 1.00 
Before Pregnancy 83 (34.2) 1056 (37.3) 0.75 (0.45, 1.25) 0.68 (0.40, 1.17) 
1st Trimester 24 (9.8) 243 (8.6) 0.93 (0.51, 1.69) 0.85 (0.45, 1.58) 
2nd Trimester** 120 (49.4) 1383 (48.9) 0.82 (0.50, 1.35) 0.69 (0.41, 1.17) 
Never Initiated 16 (6.6) 149 (5.3) 1.00 1.00 
* Extremely to very preterm: 27 to < 32 gestation weeks 
† Moderate to late preterm: 32 to < 37 gestation weeks 
‡ Full term: ≥ 37 gestation weeks 
§ Adjusted for mother’s age and parity 
** before 27 weeks 
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Figure 4.1. Study eligibility on the basis of maternal ART start time and gestational age at birth 
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< 28 weeks 
 
 Very 
preterm   
28 - < 32 
weeks 
Moderate 
preterm    
32 - <34 
weeks 
Late 
preterm   
34 - < 37 
weeks 
Term 
37 - < 42 
weeks 
Post-term 
42 or more 
weeks 
Gestation weeks      0         27          37 
 
Ineligible ART start times 
Ineligible births Eligible births 
Eligible ART start times 
  
 
4
6
 
Figure 4.2 Flow diagram of the inclusion criteria for the women included in the analysis 
66,029                 
Pregnant Women 
59,815                       
HIV Status Known 
6,853                          
HIV Positive 
4,988                        
Eligible Outcomes  
6,214 - Missing HIV Status 
in EMR 
52,962 - HIV Negative 
1799 – Delivered before 27 weeks  
66 – Multiple gestation  
 
1139                           
Before Pregnancy 
1264 - Missing ART initiation time  
650 – Initiated ART at or after 27 weeks 
 
267                             
1st Trimester 
1503                          
2nd Trimester 
3,074                        
Included in analysis  
165                      
Never Initiated  
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CHAPTER FIVE: THE POPULATION-LEVEL EFFECT OF OPTION B+ ON FEMALE-TO-  
MALE HIV TRANSMISSION IN MALAWI: A MATHEMATICAL MODELING ANALYSIS  
 
Introduction 
In 2013, an estimated 1.5 million people were newly infected with HIV in sub-Saharan 
Africa, mostly through heterosexual transmission.12 High serum viral load in HIV-infected 
persons increases the risk of transmitting the virus to their sexual partners.106  When treated 
with antiretroviral therapy (ART), HIV-infected persons have reduced concentrations of HIV viral 
load  in their plasma,107,108 semen,109,110 and cervicovaginal fluid.108 The ability of ART to reduce 
HIV viral loads has been pivotal in preventing mother-to-child transmission (MTCT),97,111 and 
reducing HIV transmission among adults.112-114 
Worldwide, efforts have been made to increase ART availability to all HIV-infected 
pregnant and breastfeeding women. The recommendations and guidelines in the 
implementation of prevention of mother-to-child transmission (PMTCT) programs have been 
revised over time as simplified, standardized, and more potent ART regimens have become 
available.98-102 In 2010, the World Health Organization (WHO) issued guidelines for PMTCT that 
included two approaches: Option A and Option B. Both Options A and B include lifelong, triple 
ART for HIV-infected pregnant women with CD4 cell count ≤ 350 cells per mm3. Under Option 
A, women with CD4 > 350 cells per mm3 start azidothymidine (AZT) as early as 14 weeks of 
gestation, followed during labor by single dose nevirapine (sdNVP) plus the first dose of 
azidothymidine / lamivudine (AZT/3TC), and then daily AZT/3TC through the first seven 
postpartum days. Under Option B, women with CD4 > 350 cells per mm3 start triple ART as 
early as 14 weeks of gestation and continue up to one week after breastfeeding cessation.   
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Limited access to CD4 cell count analysis in developing countries has been a barrier to 
rapid expansion of PMTCT programs using Option A and Option B, as both strategies 
differentiate treatment regimens according to CD4 count. In 2011, the Malawi government 
proposed and started implementing a new and simplified approach to PMTCT called Option 
B+,5 now adopted by WHO for all countries with generalized HIV epidemics.8 Under Option B+, 
all confirmed HIV-infected pregnant or breastfeeding women are started on lifelong ART 
regardless of CD4 cell count. Besides preventing MTCT, the Option B+ approach has other 
potential ancillary public health benefits beyond those offered by Option A and Option B, 
especially continued prevention of sexual HIV transmission from HIV-infected women beyond 
pregnancy and breastfeeding.5,102  
Programmatic efficiency of Option B+ over Option B has been shown in Malawi through 
a dramatic increase in the number of pregnant or breastfeeding women on ART.6 However, the 
impact of Option B+ on the adult HIV / AIDS burden through reduced heterosexual transmission 
has not been quantified in this setting. In this study, we developed a mathematical model to 
estimate the expected relative reduction in HIV incidence among men in Lilongwe, Malawi under 
Option B+ versus Option B from 2011 to 2020.   
 
Methods 
Mathematical model specification 
We developed a deterministic, compartmental model to study the effect of Option B+ on 
heterosexual HIV transmission from women to men. The model captures the population 
dynamics of women only (Figure 5.1), stratified into compartments by HIV status as HIV-
uninfected (susceptible; S) and HIV-infected (I), age cohorts (15-19, 20-24, 25-34 and 35-49), 
and pregnancy / breastfeeding status (either pregnant or breastfeeding, neither pregnant nor 
breastfeeding). HIV-infected women are further stratified by HIV disease stage (CD4 ≥500, 350 
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≤ CD4 ≤499, 200 ≤ CD4 ≤349, and CD4 < 200) and ART status  (ART naïve, on ART, and ART 
drop-outs). 
Young women enter the model population in the non-pregnant, HIV-susceptible, 15-19 
years age group and then age into older age groups at rates reciprocal to the expected time to 
be spent in each age category. Following modeling convention, both HIV-uninfected and HIV-
infected persons are removed from the population by aging out of the sexually active population 
upon reaching 50 years of age.  The initial size of the model population was based on census 
estimates for Lilongwe, Malawi.130  Model processes are described below, with corresponding 
parameter values in Tables 5.1 and 5.2.  Additional details on the modeling approach are 
provided in the supplemental material. 
 
HIV infection in women 
HIV-susceptible women become infected at an age- and calendar-time-specific 
incidence rate 157,158 that also depends on pregnant/breastfeeding status (Table 5.1).159 At the 
time of infection, women enter one of four HIV disease stages according to proportions 
estimated in the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort of infected 
persons who progress directly from primary infection to each stage:160 early asymptomatic stage 
without significant immunosuppression (CD4 ≥500), late asymptomatic stage with mild 
immunosuppression (350 ≤ CD4 ≤499), early AIDS with advanced immunosuppression (200 ≤ 
CD4 ≤349), and full-blown AIDS with severe immunosuppression (CD4 < 200). Untreated HIV 
progression from one stage to the next occurs at a constant rate, as does death due to AIDS in 
the final stage.160 
 
ART uptake, retention, and effects on HIV progression  
ART eligibility for both either pregnant or breastfeeding women and neither pregnant nor 
breastfeeding varies over time according to Malawi Government guidelines in the years since 
 50 
 
ART became available (Table 2).154,161-163 Since ART-for-health eligibility criterion for years 2000 
– 2010 was CD4 < 250 and not CD4 < 200 in Malawi, we allowed some women with 200 ≤ CD4 
≤ 349 to initiate ART during this period. Among ART-eligible women, ART initiation depends (for 
pregnant women) on ANC uptake 131,164-166 and (for both pregnant and not-pregnant women) 
observed ART uptake rates for PMTCT and health, respectively.167-169 Women drop out of 
treatment at a constant rate, with assumed values for this rate based on estimates used in 
previous mathematical modeling studies;170-177 these women are assumed not to re-initiate ART 
until their CD4 cell count falls to < 200 or they become eligible for PMTCT via pregnancy. 
Women also discontinue ART after weaning under the Option B scenario if their CD4 is above 
contemporary ART eligibility thresholds (see Comparison of Option B+ vs. Option B impact on 
female-to-male HIV transmission below). Once women meet re-initiation criteria (i.e., pregnancy 
or CD4 < 200), ART re-initiation is assumed to occur at the same rate as initial ART uptake 
among ART-naïve persons.  
Women on ART are assumed to have a long period of “effective ART” during which their 
CD4 cell count remains within the category in which they initiated ART, and their progression 
rate is assumed to be much slower compared to women not on ART.170,171,178  Women who drop 
out of ART are assumed to progress to the next CD4 cell count stratum at the same rate as 
ART-naïve women. 
 
Pregnancy and breastfeeding 
Women become pregnant at age- and calendar-time-specific fertility rates179 that further 
depend on HIV status180,181 and (for HIV-infected women) ART status.104 Women exit the 
pregnant / breastfeeding compartments at a constant rate based on the mean expected duration 
of pregnancy and breastfeeding, with mean breastfeeding duration varying over time according 
to DHS estimates.131,164-166  
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HIV transmission from women to men  
Following Bezemer et al 182 and van Sighem et al,183 HIV incidence in men is described 
by a time-varying net transmission rate, which specifies transmission as a function of the 
numbers of HIV-infected women in each compartment and the relative infectiousness 
associated with each compartment. More specifically, in our model, the net transmission rate 
from women to men is a function of the numbers and relative infectiousness of HIV-infected 
women according to disease stage, ART status, and pregnancy status. Asymptomatic women 
who are not on ART and not pregnant serve as the referent, with later disease stages and 
pregnancy resulting in higher infectiousness,184,185 and ART use resulting in decreased 
infectiousness.114,184,186  
 
Model analysis 
All analyses were performed using R software, version 3.2.0. The model code was 
formulated in a set of ordinary differential equations implemented in the  R software package 
deSolve.132 
Model fitting 
We used a Bayesian melding approach187-190 to fit our model to empirical data on HIV 
prevalence and ART uptake. In brief, we first ran 100,000 model simulations, with input 
parameter values drawn in each independent run from the prior distributions given in Tables 5.1 
and 5.2. Next, we filtered out simulations in which output values for recent ART coverage and 
overall HIV prevalence were deemed implausible.  More detail is available in the supplemental 
material, but briefly, we required that HIV prevalence among all women was consistent with 
2004 and 2010 DHS estimates for female HIV prevalence in urban settings in Malawi (as 
Lilongwe-specific estimates were unavailable),131,166 and that ART coverage for health and 
PMTCT was consistent with UNAIDS estimates in the period 2008-2010.191 Following this 
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filtering process, we assigned each surviving simulation a weight based on the likelihood of 
empirical HIV prevalence among pregnant women from ANC surveillance in Lilongwe (1987-
2007), given the input parameter values in the simulation. Finally, we resampled (with 
replacement) from the simulations, with probability of selection proportional to the assigned 
weight.  From the resampled runs we then calculated median values, along with 95% credible 
limits from the 2.5th and 97.5th percentile values, for model inputs and outputs.  
   
Comparison of Option B+ vs. Option B impact on female-to-male HIV transmission 
To estimate the projected impact of Option B+ on female-to-male transmission over the 
strategy’s first nine years of existence in Lilongwe, we ran three model scenarios from 2011 
through 2020: 1) one in which we assumed that Option B+ was the PMTCT strategy, with ART-
for-PMTCT uptake set to observed values168 in the period 2011-2014 and then fixed at the 2014 
value for the period 2014-2020; 2) one in which we assumed that Option B was the PMTCT 
strategy, with ART uptake values in the period 2011-2020 assumed to be the same as those 
assumed for Option B+; and 3) one in which we assumed that Option B was the PMTCT 
strategy, but with ART uptake values in the period 2011-2020 assumed to remain at 2011 
levels. In all three scenarios, all other parameters were fixed at 2011 values.  Thus, the key 
difference between Scenario 2 and Scenario 1 is the difference in ART discontinuation following 
breastfeeding cessation: Under Scenario 2 (Option B), women with CD4 above the national 
ART-for-health eligibility criterion (i.e., 350 in the period 2011-2014 and 500 in the period 2014-
2020) discontinued ART upon leaving the pregnant/breastfeeding compartment, but all women 
stayed on ART in Scenario 1 (Option B+). This difference also held in the comparison of 
Scenario 3 and Scenario 1, with the additional difference of increasing ART uptake associated 
with the lack of a CD4 testing requirement under Option B+ but not Option B.  More specifically, 
uptake of ART for PMTCT was assumed to increase between 2011 and 2014 in the Option B+ 
scenario (Scenario 1) but not in the Option B scenario (Scenario 3).  
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We used results from the three simulations to estimate the net transmission rate under 
each strategy each year. We then compared the net transmission rate under Option B+ and 
Option B in two sets of comparisons: Scenario 2 vs. Scenario 1 and Scenario 3 vs. Scenario 1.  
In these comparisons, we derived the relative HIV incidence reduction in men due to PMTCT 
Option B+ at each time point by dividing the net transmission rate from women under Option B+ 
(Scenario 1) by the corresponding net transmission rate under each of the Option B scenarios 
(Scenarios 2 and 3) separately.  
 
Results 
The Bayesian melding procedure produced 12,000 unique HIV prevalence curves 
among pregnant/breastfeeding women that were in good agreement with the empirical HIV 
prevalence data from ANC surveillance in Lilongwe (Figure 5.2). Using the median from the 
simulations, we estimated that the HIV prevalence among pregnant women peaked in 1998, 
(23.6%; 95% credible intervals (CI): 19.9 – 27.6), dropped to 17.9% (95% CI: 15.6 – 20.3) in 
2008, and then to 15.1% (95% CI: 13.0 – 17.4) in 2011.  The corresponding HIV prevalence in 
the overall female population in 2004 and 2010 was 21.2% (95% CI: 18.9 – 22.4) and 17.4% 
(95% CI: 15.5– 19.0) (results not shown), which are within the range of DHS estimates of 2004 
and 2010 among women for Malawi urban areas, respectively.     
Estimated female-to-male HIV transmission from 2011 through 2020 was lower 
assuming Option B+ than assuming Option B under both sets of Option B scenarios (Figure 
5.3). Comparing Option B+ to the Option B scenario in which ART uptake values in the period 
2011-2020 were assumed to be the same as those assumed for Option B+ (i.e., in the 
comparison of Scenario 2 to Scenario 1), the estimated relative HIV incidence (RI) under Option 
B+ was 4% lower (median RI = 0.96; 95% CI: 0.94 – 0.97) in 2015 and was projected to be 7% 
lower (median RI = 0.93; 95% CI: 0.90 – 0.95) by 2020. Comparing Option B+ to the Option B 
scenario in which ART uptake values in the period 2011-2020 were assumed to remain at 2011 
 54 
 
levels (i.e., the comparison of Scenario 3 to Scenario 1), the estimated RI under Option B+ was 
14% lower (median RI = 0.86; 95% CI: 0.84 – 0.88) in 2015 and was projected to be 21% lower 
(median RI = 0.79; 95% CI: 0.74 – 0.83) by 2020.  
Model-predicted ART coverage among not-pregnant/not-breastfeeding women 
increased from 40% (95% CI: 34 - 47) of treatment-eligible women in 2011 to 85% (95% CI: 78 - 
92), 78% (95% CI: 72 - 84), and 71% (95% CI: 64 - 77) in 2020 under scenarios 1, 2, and 3, 
respectively (results not shown). Estimated ART coverage among pregnant/breastfeeding 
women increased from 22% (95% CI: 18 - 26) in 2011 to 78% (95% CI: 73 - 82), 76% (95% CI: 
72 - 80), and 68% (95% CI: 63 - 73) in 2020 under the three scenarios. 
  
Discussion 
Our mathematical modeling study provides the first quantitative estimates of HIV 
incidence reductions associated with Option B+ in Malawi, the first country to implement this 
PMTCT strategy at a national level.  Our results suggest that the Option B+ strategy has 
considerable potential to reduce female-to-male HIV transmission in addition to its benefits for 
preventing vertical transmission. The incidence reductions that we observed were particularly 
notable when we assumed that Option B+ affected not only the duration of therapy (by calling 
for lifelong treatment even after breastfeeding cessation), but also the proportion of pregnant 
women initiating ART to begin with (by removing CD4 testing barriers). As reflected in our 
model, national treatment guidelines recently increased the CD4 threshold for ART-for-health 
from 350 to 500, such that more women in the “Option B” scenario now remain eligible for ART 
after breastfeeding cessation than was the case prior to 2014.  This higher CD4 threshold 
results in a smaller difference in ART duration under Option B+ vs. Option B, such that 
increased ART uptake due to removal of CD4 testing barriers may be an important and 
underappreciated mechanism for Option B+ to reduce heterosexual transmission in this region.  
 55 
 
 In sub-Saharan Africa, the need for PMTCT remains high and is likely to increase. A 
large number of new and prevalent HIV infections in the region are among reproductive-aged 
women.55 The rapid expansion of ART in this region should continue to result in growing 
proportions of women receiving ART, and ART-induced rebounds from HIV-related sub-
fertility103-105 will likely result in increased proportions of HIV-infected women in antenatal clinic 
populations. ART adherence support in these settings could help to ensure that the benefits of 
ART – both for PMTCT and for the prevention of heterosexual transmission – can be realized in 
the Option B+ era.   
Our estimated incidence reductions are relatively consistent with – but somewhat lower 
than – the results of the single previous mathematical modeling study that estimated the impact 
of different PMTCT strategies on heterosexual transmission.192   In the application of this earlier 
model to four separate settings (Kenya, Zambia, South Africa, and Vietnam), Option B+ was 
estimated to avert 18% (in Kenya) to 115% (in South Africa) more heterosexual transmissions 
than Option B with a CD4 eligibility threshold of 350 for ART for health, and 17% – 61 % more 
infections than Option B when the CD4 threshold was 500.  In our comparison of Option B+ vs. 
Option B, the ART-for-health CD4 threshold was 350 from 2011 through 2013, and 500 from 
2014 through 2020.  As such, the reductions of 17% - 61% obtained for the CD4 threshold of 
500 in the prior study – particularly estimates of 17% in Kenya and 25% in Zambia – are most 
relevant to our own.  We note that our estimated reductions of 7% (5%-10%) and 21% (17%-
26%) in 2020 relate to a period of only nine years (2011-2020), whereas the estimated benefits 
of Option B+ in the earlier modeling study were accrued over a 35-year period, potentially 
explaining the lower estimates that we obtained.        
Mathematical models have also been used to evaluate the benefits of Option B and 
Option B+ in terms of mother-to-child transmission, infant and maternal health, and cost-
effectiveness. In a model based largely on parameters calculated from programmatic data in 
Malawi, Option B+ resulted in less MTCT and more women already on ART during their second 
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pregnancy than under Option B.193 Greater reductions in MTCT using Option B+ were also 
reported in a model focusing on Kenya, Zambia, South Africa and Vietnam.192 A model based 
on data from Zimbabwe showed increased life expectancy among infants and their mothers 
under Option B+ vs. Option B.194 In each of these models, Option B+ was found to be more 
cost-effective than Option B in all sub-Saharan African countries except South Africa. 
Our model incorporated numerous details underlying demographic and transmission 
dynamics, including age stratification, time-varying parameter values, and the effects of HIV and 
ART on survival, fertility, and infectiousness. We based our model parameters largely on 
Malawi-specific sources, including DHS reports, UNAIDS estimates, and local programmatic 
data. Our Bayesian melding approach allowed us to accurately reproduce HIV prevalence 
trends in this setting – both in ANC populations and the general female population overall – 
along with trends in ART coverage. This model fitting procedure also allowed us to account for 
uncertainty in input parameters and express uncertainty (in the form of credible limits) around 
our model outputs.     
Mathematical modeling results depend on simplifying assumptions that are necessary 
for the development of tractable models.  In our case, we only considered incidence reductions 
from women to men, without taking into account the subsequent reductions in incidence that 
would occur among women as a result of reduced HIV prevalence in men, which would then 
result in further incidence reductions in men, and so on. The omission of these non-linear 
feedback loops will necessarily result in underestimation of overall incidence reductions 
attributable to Option B+; however, we attempted to minimize this underestimation by limiting 
our time horizon to a relatively short period of nine years. We also note that we did not consider 
acute HIV infection and its attendant increased infectiousness in our model.  We deliberately 
chose this simplification because recognition of and treatment during acute HIV is rare in this 
region. Because neither Option B nor Option B+ would affect this reality, we do not expect that 
this analytical choice affected the results.   
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An additional simplification in our model was the assumption that persons who 
discontinue ART progress through disease stages at the same rate as ART-naïve persons. As 
rapid increases in viral load and decreases in CD4 counts can follow ART interruption,195 this 
assumption may have particularly underestimated the proportion of women in later HIV stages 
in the Option B scenarios, as more women discontinue ART under Option B than Option B+.  
The net effect of this potential bias on the comparison of Option B vs. Option B+ incidence 
reductions is difficult to predict, however. On the one hand, greater underestimation of women in 
later disease stages under Option B (compared to Option B+) could result in greater 
underestimation of HIV incidence in the Option B scenario than in the Option B+ scenario, as 
women in later HIV stages are assumed to have higher biological infectiousness. Incidence 
reductions attributable to Option B+ would thus be over-estimated. On the other hand, faster 
progression results in higher mortality (and thus a shorter duration of infectiousness), so greater 
underestimation of progression rates under Option B than under Option B+ could result in 
overestimation of HIV incidence in the Option B scenario, resulting in underestimation of the 
relative incidence reduction attributable to Option B+.         
Despite these limitations, our findings add to existing evidence that Option B+ can 
substantially reduce adult HIV incidence in sub-Saharan Africa, even in an era when ART-for-
health begins at CD4 counts as high as 499 cells/mm3. These gains may be particularly great if 
the removal of CD4 testing barriers by Option B+ results in improved ART uptake for PMTCT. 
Option B+ is now being implemented in most countries in sub-Saharan Africa where HIV is 
endemic and fertility is high, suggesting that HIV incidence declines in this region may be even 
greater than has been projected on the basis of ART-for-health expansion alone. As the optimal 
realization of these benefits will depend on ART adherence and retention, and because long-
term trends in ART adherence and retention under Option B+ remain to be seen, countries 
implementing Option B+ should make deliberate efforts to encourage and monitor ART 
adherence and retention, both during pregnancy and after breastfeeding cessation. 
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Tables and Figures 
Table 5.1 Input parameter descriptions and values 
 
Parameter 
 
Description 
 
Value or distribution* 
 
Source 
n Initial size of the entire female population aged 15- 49 years 
in Lilongwe 
 
271541 
 
130 
𝜂 Rate at which young non-pregnant susceptible women enter 
the sexually active age per year 
 
0.029 
 
Calculated 
Λ(𝑡) HIV incidence rate at year t Supplement 
Table A2.1 
 
156 
 
Relative HIV incidence rate  by age and pregnant/breastfeeding status 
𝛿1 Relative HIV incidence rate comparing women in age cohort 
15 – 19 to women in age cohort 25 - 34 
 
0.52 
 
 
157 
 
 
𝛿2 Relative HIV incidence rate comparing women in age cohort 
20 – 24 to women in age cohort 25 – 34 
 
1.02 
* For parameter values that varied across runs, distributions are given as uniform (lower limit, upper limit) or normal (mean, SD) 
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Table 5.1 Input parameter descriptions and values (continued) 
 
Parameter 
 
Description 
 
Value or distribution* 
 
Source 
𝛿4 Relative HIV incidence rate comparing women in age cohort 
35 – 49 to women in age cohort 25 - 34 
 
0.59 
 
157 
ln (𝜛) Natural log of relative HIV incidence rate comparing either 
pregnant or breastfeeding women to neither pregnant nor 
breastfeeding women 
Normal (0.77, 0.23)  
158 
 
Distribution of HIV stages immediately after primary infection 
𝜋1 Proportion of newly infected women going directly to 
asymptomatic stage 1 (CD4>500) 
Normal (0.76, 0.013)  
 
159 
 
𝜋2 Proportion of newly infected women going directly to 
asymptomatic stage 2 (CD4 350-500) 
Normal (0.19, 0.013) 
* For parameter values that varied across runs, distributions are given as uniform (lower limit, upper limit) or normal (mean, SD) 
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Table 5.1 Input parameter descriptions and values (continued) 
 
Parameter 
 
Description 
 
Value or distribution* 
 
Source 
𝜋3 Proportion of newly infected women going directly to 
asymptomatic stage 3 (CD4 200-350)  
 
Normal (0.05, 0.008) 
 
 159 
𝜋4 Proportion of newly infected women going directly to AIDS 
stage (CD4 < 200) 
 
Normal (0.00, 0.003) 
 
Duration of untreated HIV infection stages; effect of ART 
1
𝛾1⁄  
Duration of HIV infection in asymptomatic stage 1 (years) Normal (3.32, 0.13)  
 
159 
 
1
𝛾2⁄  
Duration of HIV infection in  asymptomatic stage 2 (years) Normal (2.70, 0.12) 
1
𝛾3 ⁄  
Duration of HIV infection in  asymptomatic stage 3 (years) Normal (5.50, 0.47) 
1
𝛾4⁄  
Duration of HIV infection in AIDS stage (years) Normal (5.06, 0.94) 
𝜑 Relative disease progression rate due to being on ART Uniform (0.2, 0.5)  169, 170, 177 
* For parameter values that varied across runs, distributions are given as uniform (lower limit, upper limit) or normal (mean, SD) 
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Table 5.1 Input parameter, description and values (continued) 
 
Parameter 
 
Description 
 
Value or distribution* 
 
Source 
 
ART uptake and drop-out rates  
𝜙ℎ Annual ART uptake rate for health for eligible not pregnant  
women 
 
Table 2 
 
–166 - 168 
𝑏ℎ Annual ART uptake rate for PMTCT for pregnant 
/breastfeeding women 
 
Table 2 
 
–166 - 168 
𝜓0,ℎ Annual ART drop-out rate for non-pregnant/breastfeeding Uniform (0.03, 0.1) 169 - 176 
𝜓1,ℎ Annual ART drop-out rate  for PMTCT Uniform (0.03, 0.1) –169 - 176 
 
𝜈ℎ 
Proportion of HIV infected pregnant / breastfeeding women 
on ART and in HIV disease stage h who are eligible to 
continue ART after stopping breastfeeding (Option B vs B+) 
 
Supplement 
Table A2.2 
 
–153, 160 -162 
* For parameter values that varied across runs, distributions are given as uniform (lower limit, upper limit) or normal (mean, SD) 
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Table 5.1 Input parameter, description and values (continued) 
 
Parameter 
 
Description 
 
Value or distribution* 
 
Source 
 
Aging rate from one age group to the next 
𝜁1 Aging rate from 15-19 to 20-24 (per year) 0.2  
Calculated as 
reciprocal of total 
number of years in 
age bracket  
𝜁2 Aging rate from 20-24 to 25-34 (per year) 0.2 
𝜁3 Aging rate from 25-34 to 35-49 (per year) 0.1 
 
𝜁4 
Aging rate from  35-49 to > 49 (aging out of the sexually 
active population)  (per year) 
 
0.07 
 
Fertility and ANC Parameters 
𝑓𝑐 Age- and calendar time-specific fertility rate for susceptible 
women in age cohort c (per year) 
Supplement 
Table A2.3 
178 
𝜔 calendar time-specific rate at which women exit the 
pregnancy and breastfeeding status (per year) 
Supplement 
Table  A2.4 
131, 163 - 165 
* For parameter values that varied across runs, distributions are given as uniform (lower limit, upper limit) or normal (mean, SD) 
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Table 5.1 Input parameter, description and values (continued) 
Parameter Description Value or distribution* Source 
𝑥 
 
Age- and calendar time-specific rate at which women 
attended antenatal care (per year) 
Supplement 
Table A2.5 
 
131, 163 - 165 
ln (𝑅𝑛) Natural log of relative fertility rate for HIV+ not on ART  
compared to HIV uninfected 
 
Normal (0.31, 0.12) 
 
179, 180 
ln (𝑅𝑥) Natural log of relative fertility rate for HIV+ on ART compared 
to HIV+ not on ART 
 
Normal (0.55, 0.20) 
 
104 
Relative HIV infectiousness 
𝜌1 CD4: 350-499 vs  CD4 ≥ 500 0.93  
183 𝜌2 CD4:  200 – 349 vs CD4 ≥ 500 1.53 
𝜌3 CD4 <  200 vs CD4 ≥ 500 4.83 
𝜅 Relative HIV infectiousness comparing individuals on ART to 
individuals not on ART 
 
0.08 
 
114, 183, 185 
𝛼 Relative HIV infectiousness comparing pregnant women to 
not pregnant women 
 
2.47 
 
185 
* For parameter values that varied across runs, distributions are given as uniform (lower limit, upper limit) or normal (mean, SD) 
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Table 5.2 ART uptake rates for health and PMTCT among eligible women 
 
ART program 
 
CD4 category 
Year 
2000 - 2005‡ 2006 - 2010‡ 2011§ 2012§ 2013§ 2014¥ 
 
 
 
ART for Health 
≥500 0 0 0 0 0 0 
350 - 499 0 0 0 0 0 Uniform 
(0.49, 0.61) 
 
200 - 349† 
Uniform 
(0.05, 0.10) 
Uniform 
(0.10, 0.25) 
 
Uniform(0.49, 0.61) 
 
< 200† 
Uniform 
(0.05, 0.10) 
Uniform 
(0.10, 0.25) 
 
Uniform(0.49, 0.61) 
 
 
 
PMTCT* 
≥500 0 0  
 
Uniform 
(0.45, 0.50) 
 
 
Uniform 
(0.65, 0.70) 
 
 
Uniform 
(0.60, 0.65) 
 
 
Uniform 
(0.65, 0.70) 
350 - 499 0 0 
 
200 - 349† 
Uniform 
(0.05, 0.10) 
Uniform 
(0.10, 0.25) 
< 200† Uniform 
(0.05, 0.10) 
Uniform 
(0.10, 0.25) 
Sources: 1. Ministry of Health. Quarterly Report Antiretroviral Treatment Programme in Malawi. Lilongwe, Malawi: 2004 – 2009 
2. Ministry of Health. Intergrated HIV Program Quarterly Reports Lilongwe, Malawi: 2010 - 2014. 
3. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS 
medicine. 2011;8(7):e1001056. 
* Values shown for 2011-2015 were applied in Scenarios 1 and 2.  The value for 2011 was held constant from 2011 onward in 
Scenario 3. 
† The uptake (years 2000 – 2010) were applied to the estimated proportion of women in the 200-349 stratum who had CD4 < 250 
when the threshold was CD4 < 250 
‡ 2000 - 2010 corresponds to CD4 < 250 ART eligibility criteria 
§ 2011 - 2013 corresponds to CD4 < 350 ART eligibility criteria  
¥ 2014 corresponds to CD4 < 500 ART eligibility criteria 
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Figure 5.1 Simplified model diagram  
 
 
The population of women in the model is stratified by HIV status as HIV-uninfected  𝑆𝑐
𝑝
 , and HIV-infected 𝐼𝑐
𝑝,ℎ,𝑎
, where the subscript c 
indicates age cohort (1=15-19, 2=20-24, 3=25-34, and 4=35-49), the subscript p indicates pregnancy / breastfeeding status (0 = not 
pregnant / breastfeeding, 1 = pregnant / breastfeeding), the subscript h represents HIV stage among HIV-infected women (1 = CD4 
≥500, 2 =  350 ≤ CD4 ≤499, 3 = 200 ≤ CD4 ≤349, and 4 = CD4 < 200), and the subscript a represents ART status among HIV-
infected women (0 = ART naïve, 1 = on ART, 2 = off ART).  The “stacked” boxes represent disease stages. Not shown in the diagram 
is the process of aging from one age group to the next. 
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Figure 5.2 Antenatal HIV prevalence in Lilongwe, Malawi 
 
HIV prevalence data from Lilongwe antenatal clinic are shown as points with corresponding 95% confidence intervals. The solid line 
is the median HIV prevalence and the dashed lines are the 2.5th and 97.5th percentile at each time point generated from the model 
output.  
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Figure 5.3 Relative HIV incidence in men comparing Option B+ to Option B strategies 
 
The solid line is the median relative HIV incidence in men and the dashed lines are the 2.5th and 97.5th percentile at each time point 
generated from the model output.  
Option B+ vs Option B – Scenario 2 compares Option B+ to Option B, with ART uptake values in the period 2011-2020 assumed to 
be the same for Option B (scenario 2) as those assumed for Option B+ (scenario 1) 
Option B+ vs Option B – Scenario 3 compares Option B+ to Option B, with ART uptake values in the period 2011-2020 assumed to 
remain at 2011 levels for the Option B scenario (scenario 3) 
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CHAPTER SIX: DISCUSSION 
Option B+ is a simplified approach to PMTCT5  that has now been recommended by 
WHO for all countries with a generalized HIV epidemic.8 Under Option B+, all confirmed HIV-
infected pregnant or breastfeeding women are started on life-long ART regardless of WHO 
Clinical Stage or CD4 cell count.  Besides preventing MTCT, the Option B+ approach has other 
potential ancillary public health benefits beyond those offered by Option A and Option B, 
including improved infant and maternal health, greater uptake of ART due to removal of CD4-
related obstacles, and continued prevention of sexual HIV transmission from HIV-infected 
women beyond pregnancy and breastfeeding.5,102 
In this work, we sought to advance understanding of ART effects in the Option B+ era. 
More specifically, we assessed the relationship between ART exposure during pregnancy and 
preterm birth, and we quantified the impact of Option B+ on the adult HIV / AIDS burden through 
reduced heterosexual transmission.  The results and implications of each analysis are 
summarized below.  
 
Aim 1: Time of ART initiation and preterm birth 
Summary of Results 
In Aim 1, we estimated the risk of preterm birth among singleton live infants born to HIV-
infected women delivering at ≥ 27 weeks of gestation at Bwaila Hospital in Lilongwe, Malawi 
between April 1, 2012 and November 15, 2015. We compared the risk of preterm birth 
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according to ART exposure during pregnancy and (for those on ART at delivery) time of ART 
initiation during pregnancy. We hypothesized that a) women who are on ART during pregnancy 
have a lower risk of delivering preterm infants than those not on ART, and b) women who 
initiate ART earlier in pregnancy have a lower risk of delivering preterm infants compared to 
women who initiate ART later or never initiated ART during pregnancy. 
Among 3074 women who had singleton live births at 27+ weeks of gestation and 
initiated ART before 27 weeks of gestation or never initiated ART during pregnancy, most 
women had initiated ART before pregnancy (N=1139, 37.0%) or during the second trimester 
(N=1503, 48.9%).  A total of 731 preterm births were observed during the study period (risk = 
24%; 95% CI: 22% - 25%). 
In the analysis of all preterm births vs full term births, there was not a clear trend in the 
relationship between timing of ART initiation and risk of preterm birth; the aRRs for preterm birth 
were 0.78 (95% CI: 0.57 – 1.08), 1.03 (95% CI: 0.72 – 1.49), and 0.92 (95% CI: 0.67 – 1.25) for 
initiating ART before pregnancy, during the 1st trimester, and during the 2nd trimester, 
respectively, after adjustment for mother’s age and parity.  ART initiation at any point before 
delivery appeared strongly protective against extremely to very preterm birth (aRR = 0.43; 95% 
CI: 0.26 – 0.72).  Our results also suggested that ART was protective against extremely to very 
preterm birth at all three initiation times assessed separately: before pregnancy (aRR = 0.42; 
95% CI: 0.24 – 0.73), in the 1st trimester (aRR = 0.54; 95%CI: 0.27 – 1.10), and in the 2nd 
trimester (aRR = 0.42; 95% CI: 0.24 – 0.72). 
 
Interpretation 
Our findings highlight the importance of HIV-infected women being on ART during 
pregnancy for the benefit to the developing fetus as well as their own health. ART during 
pregnancy did not appear to increase the risk of preterm birth in our study, and initiation prior to 
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conception appeared protective. Importantly, ART initiation prior to conception appeared 
strongly protective against extremely to very preterm birth (27 - < 32 weeks of gestation). 
 
Public health significance 
Option B+ is now being implemented in most countries in sub-Saharan Africa with a 
generalized HIV epidemic8  and high proportion of preterm births.23  As the Option B+ program 
matures, we expect the proportion of women on lifelong ART following a prior pregnancy to 
grow. Consequently, we expect the proportion of women on ART prior to conception to 
increase.  Our finding that the risk of preterm birth was much lower in this group gives us hope 
that incidence of preterm birth among HIV-infected mothers will decrease as the time since 
Option B+ implementation increases.  
Neonatal and infant mortality is high among preterm births, with only 30% of babies born 
between 28 and 32 weeks in low-income countries surviving.27 Our finding that being on ART 
during pregnancy is protective against extremely to very preterm birth, regardless of time of 
ART initiation, is especially encouraging. Increased ART uptake in the Option B+ era could 
therefore have a profound impact on neonatal mortality in developing countries where advanced 
nursery facilities for very preterm babies are not readily available.  
 
Limitations 
Gestational age assessment in this study was based on last menstrual period, which is 
not as accurate as ultrasound in dating pregnancy. Our determination of preterm status and 
ART initiation status based on gestational age may have resulted in misclassified preterm status 
and ART initiation time within pregnancy. We also note that our study population was confined 
to those who initiated ART before 27 weeks and gave birth at 27+ weeks, so we were not able 
to assess the effects of third-trimester ART initiation or the risk of extremely preterm birth prior 
to 27 weeks. 
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Our analysis is based on routinely collected data which is often characterized by limited 
inclusion of relevant variables, missing data, and/or erroneous data. We did not have 
information on several variables that may have resulted in unmeasured (and unaddressed) 
confounding.  In particular, we did not have information on ART adherence and antenatal care 
attendance prior to delivery. As we did not have information on ART adherence or continuity, 
ART-exposed women were assigned to exposure categories according to timing of ART 
initiation regardless of whether they were truly on therapy during the entire period or not. 
However, ART adherence during pregnancy is generally very high, so we would not expect any 
unmeasured variability in adherence to have substantially affected our results.  
HIV-infected women not previously on ART are initiated on life-long ART during an ANC 
visit,154 in addition to standard prenatal care.  In the likely event that the women who had never 
initiated ART prior to delivery were less likely to have had access to prenatal care, then the 
higher risk of preterm births among those who did not initiate ART may not be fully attributable 
to lack of ART during pregnancy. 
 
Future Research Directions 
Now that Option B+ is being implemented in many developing countries, there will be a 
continued need and new opportunities for improving our understanding of the effect of ART 
duration on birth outcomes.  In this study, we only estimated the risk of preterm birth, using 
routinely collected clinical data. Well-designed prospective cohort studies that follow HIV-
infected pregnant women from antenatal care up to delivery and collect data on important 
covariates would provide opportunities to estimate the causal effect of ART on preterm birth.  
Such studies could also assess the effects of ART on other birth outcomes such as stillbirth, low 
birthweight and congenital development issues.   
As described above and in earlier chapters, ART duration during pregnancy is 
intrinsically linked to length of gestation, making it challenging to estimate the effect of ART 
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across the full pregnancy spectrum.  To circumvent this complexity, we restricted our analysis to 
women who initiated ART before 27 weeks of gestation or never initiated ART and delivered at 
≥ 27 weeks of gestation. Future studies with innovative causal inference methodologies may 
allow assessment of ART initiation timing and its effects on preterm birth without the restrictions 
we imposed.  
 
Aim 2: Option B+ and female-to-male HIV transmission 
Summary of Results 
In this aim, we developed a mathematical model to estimate the expected relative 
reduction in HIV incidence among men in Lilongwe, Malawi under Option B+ versus Option B. 
Our hypothesis was that ART initiation among HIV-infected pregnant women under Option B+ 
would provide greater reductions in female-to-male transmission than under Option B. 
Comparing Option B+ to Option B with the assumption that ART uptake values in the 
period 2011-2020 were the same for both strategies, the estimated relative incidence (RI) under 
Option B+ was 4% lower (median RI = 0.96; 95% CI: 0.94 – 0.97) in 2015 and was projected to 
be 7% lower (median RI = 0.93; 95% CI: 0.90 – 0.95) by 2020. Comparing Option B+ to the 
Option B scenario in which ART uptake values in the period 2011-2020 were assumed to 
remain at 2011 levels (i.e., not to increase as they did under Option B+), the estimated RI under 
Option B+ was 14% lower (median RI = 0.86; 95% CI: 0.84 – 0.88) in 2015 and was projected to 
be 21% lower (median RI = 0.79; 95% CI: 0.74 – 0.83) by 2020.  
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Interpretation 
Heterosexual HIV transmission is the main mode of HIV transmission in the sub-
Saharan Africa region. In addition to preventing MTCT, our results suggest that the Option B+ 
strategy has considerable potential to reduce female-to-male HIV transmission over its first nine 
years, particularly if it greatly increases ART uptake.  
 
Public health significance 
More reproductive-aged women are expected to be on ART due to initiation during 
pregnancy as Option B+ matures in sub-Saharan Africa. Our findings suggest that as more 
women are started on ART during pregnancy and continue for life, female-to-male HIV 
transmission will decrease.  As this ancillary benefit of reducing transmission will be maximized 
with high ART adherence, countries implementing Option B+ should strive to encourage 
adherence to ART during pregnancy and after breastfeeding cessation. If high adherence can 
be maintained, then the expansion of Option B+ in this region could result in greater HIV 
incidence reductions than have been predicted on the basis of expanded ART-for-health alone.  
  
Limitations 
Mathematical modeling involves simplifying assumptions in order to develop tractable 
models. As a simplification, we only focused on female-to-male transmission, thus ignoring the 
resultant reduction in male-to-female transmission due to reduced HIV prevalence among 
males. As such, the reduction in overall heterosexual incidence attributable to Option B+ will 
likely be larger than estimated for female-to-male transmission only. We also assumed that 
persons who discontinue ART progress through disease stages at the same rate as ART-naïve 
persons, although rapid increases in viral load and decreases in CD4 counts can follow ART 
interruption. As described in Chapter 6, this assumption may have disproportionately 
underestimated the proportion of women in later HIV stages in the Option B scenarios (versus 
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the Option B+ scenario), but the effect of this underestimation on male-to-female transmission 
reductions is difficult to predict in our highly complex model. 
 
Future Research Directions  
Heterosexual HIV transmission is a complex process that is affected by many factors, 
including sexual mixing patterns, sexual contact rates, and the probability of transmission per 
sexual contact. Our model and another previous model 192  did not model heterosexual 
transmission as an explicit function of these phenomena. In both of these models only the 
relative HIV incidence reduction in men was evaluated without taking into account the 
subsequent reductions that would occur among women as a result of reduced HIV prevalence in 
men. Future transmission modeling work comparing Option B+ to Option B could incorporate 
male model compartments and explicitly model male-female interactions, allowing estimation of 
absolute reductions in HIV incidence and inclusion of non-linear dynamics. Perhaps more 
importantly, updated models may be necessary as treatment guidelines continue to evolve. 
Additional models developed for other settings that implement Option B+ could also expand our 
understanding of PMTCT programs’ ancillary benefits for heterosexual transmission.  
 
Conclusions 
HIV is pandemic in sub-Saharan Africa, with particularly high incidence and prevalence 
among reproductive-aged women. Encouraging reductions in mother-to-child transmission have 
occurred because of the effectiveness of ART in preventing vertical transmission. Here we have 
shown that PMTCT programs – in particular, the Option B+ strategy – have additional public 
health benefits apart from preventing mother-to-child transmission.  
 Our results indicated that PMTCT Option B+ may reduce the risk of extremely to very 
preterm birth among HIV-infected women by increasing the likelihood that they will be on ART 
during pregnancy, and that it may reduce the risk of preterm birth overall by increasing the 
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likelihood that HIV-infected women will be on ART prior to subsequent conceptions. We also 
found that compared to the Option B strategy, the Option B+ strategy is likely to prevent more 
cases of female-to-male transmission, conferring additional benefits beyond the PMTCT for 
which it is primarily intended.  Furthermore, Option B+ enables an additional pathway for ART 
uptake in sub-Saharan Africa, allowing greater reductions in population-level HIV incidence than 
would be expected from “ART-for-health” alone.  As such, Option B+ appears to be very positive 
addition to the HIV treatment and prevention arsenal in the current era of the HIV epidemic. 
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APPENDIX 1: AIM 2 MODEL EQUATIONS 
 
Model structure and equations 
 
Model compartments and parameter description  
Our model was implemented using differential equations capturing the dynamics of 
women in the population compartments as follows: 
𝑆𝑐
𝑝    represent susceptible women in age cohort 𝑐 (1, 2, 3 , 4) and pregnant/breastfeeding status 
p (0, 1). 
𝐼𝑐
𝑝,ℎ,𝑎
 represent HIV infected women in age cohort 𝑐, pregnant/breastfeeding status p (0, 1), HIV 
disease stage  h (1, 2, 3, 4),  and ART status  a (0,1, 2). 
Below are the definitions of the parameters in the model: 
η(𝑡) is rate at which young non-pregnant susceptible women enter the sexually active age at 
time t 
𝜆𝑐(𝑡) is the age- (c) and calendar time-specific HIV incidence rate for not  pregnant / 
breastfeeding women at time t 
𝜛 is the relative HIV incidence rate comparing pregnant/breastfeeding women to not pregnant 
women 
𝛿𝑐 is the relative HIV incidence rate comparing women in age c to women in age cohort 3 
𝜋ℎ  is the proportion of newly HIV-infected women progressing directly to HIV disease stage h 
𝜙ℎ(𝑡) is the calendar time-specific ART initiation rate among neither pregnant nor breastfeeding 
women eligible for ART for health in HIV disease stage h . 
𝑥(𝑡) is age- and  calendar time-specific antenatal uptake  rate 
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 𝑏ℎ(𝑡) is the calendar time-specific ART uptake rate for PMTCT among either pregnant or 
breastfeeding women under the PMTCT program being considered at time t. (option A, Option 
B, or  Option B+) 
𝜓0,ℎ is the annual ART dropout rate among neither pregnant nor breastfeeding women in HIV 
disease stage h 
𝜓1,ℎ is the annual ART dropout rate among either pregnant or breastfeeding women in HIV 
disease stage h.  
𝜔(𝑡)  is the calendar time-specific rate at which women exit the pregnancy and breastfeeding 
status      (𝜔 =  1 𝑝𝑟𝑒𝑔𝑛𝑎𝑛𝑐𝑦 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 + 𝑏𝑟𝑒𝑎𝑠𝑡𝑓𝑒𝑒𝑑𝑖𝑛𝑔 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛⁄ ) 
𝜈ℎ(𝑡)   is the calendar time and HIV disease stage -specific proportion of HIV infected pregnant / 
breastfeeding women on ART eligible to continue ART after stopping breastfeeding 
𝑓𝑐(𝑡) is the age- and calendar time-specific fertility rate for HIV-uninfected women in age cohort 
c 
𝑅𝑛 is the relative fertility rate comparing untreated HIV infected women in age category c to HIV 
uninfected women in age cohort c  
𝑅𝑥 is the relative fertility rate comparing HIV infected women on ART to untreated HIV-infected 
women  
𝛾ℎ  is the HIV disease progression rate for individuals in disease stage h. 
𝜑  is the effect of ART on HIV disease progression 
𝜁𝑐 is the rate at which women age from cohort c to age cohort c+1 (𝜁𝑐 =  
1
𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙 𝑐⁄  ) 
𝜌ℎ Relative HIV infectiousness due to disease stage comparing stages 2, 3, 4 to stage 1 
𝜅  Relative HIV infectiousness comparing individuals on ART to individuals not on ART 
𝛼 Relative HIV infectiousness comparing pregnant women to not pregnant women 
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Description of the model equations 
Using the parameters described above, we used differential equations to describe the rates 
of change in the women population compartments as follows: 
a. Not currently pregnant/breastfeeding HIV uninfected women  
i. 
𝑑𝑆1
0
𝑑𝑡
= η + 𝜔𝑆1
1 − (𝜋1 + 𝜋2 + 𝜋3 + 𝜋4)𝜆1
𝑟𝑆1
0 − 𝑓1𝑆1
0 − 𝜁1𝑆1
0 for r = 1, 2, 3 
ii. 
𝑑𝑆𝑐
0
𝑑𝑡
= 𝜔𝑆𝑐
1 + 𝜁𝑐−1𝑆𝑐−1
0 − (𝜋1 + 𝜋2 + 𝜋3 + 𝜋4)𝜆𝑐
𝑟𝑆𝑐
0 − 𝑓𝑐𝑆𝑐
0 − 𝜁𝑐𝑆𝑐
0  for c = 2, 3, 4;    
r = 1, 2, 3 
b. Currently pregnant/breastfeeding HIV uninfected women  
i. 
𝑑𝑆1
1
𝑑𝑡
= 𝑓1𝑆1
0 − (𝜋1 + 𝜋2 + 𝜋3 + 𝜋4)𝜛𝜆1
𝑟𝑆1
1 − 𝜔𝑆1
1 − 𝜁1𝑆1
1  for r = 1, 2 , 3  
ii. 
𝑑𝑆𝑐
1
𝑑𝑡
= 𝑓𝑐𝑆𝑐
0 + 𝜁𝑐−1𝑆𝑐−1
1 − (𝜋1 + 𝜋2 + 𝜋3 + 𝜋4)𝜛𝜆𝑐
𝑟𝑆𝑐
1 − 𝜔𝑆𝑐
1 − 𝜁𝑐𝑆𝑐
1   for c = 2, 3, 4;  
 r = 1, 2, 3 
c. Not currently pregnant/breastfeeding HIV infected women 
ART naïve    
i. 
𝑑𝐼1
0,1,0
𝑑𝑡
= 𝜋1𝜆1 
𝑟 𝑆1
0 + 𝜔𝐼1
1,1,0 − 𝛾1𝐼1
0,1,0 − 𝑅𝑛𝑓1𝐼1
0,1,0 − 𝜙1𝐼𝑐
0,1,0 − 𝜁1𝐼1
0,1,0   for r = 1, 2, 3 
ii. 
𝑑𝐼𝑐
0,1,0
𝑑𝑡
= 𝜋1𝜆𝑐
𝑟𝑆𝑐
0 + 𝜁𝑐−1𝐼𝑐−1
0,1,0 + 𝜔𝐼𝑐
1,1,0 − 𝛾1𝐼𝑐
0,1,0 − 𝑅𝑛𝑓𝑐𝐼𝑐
0,1,0 − 𝜙1𝐼𝑐
0,1,0 − 𝜁𝑐𝐼𝑐
0,1,0 for c = 2, 3, 
4;  r = 1, 2, 3 
iii. 
𝑑𝐼1
0,ℎ,0
𝑑𝑡
= 𝜋ℎ𝜆1
𝑟𝑆1
0 + 𝛾ℎ−1𝐼1
0,ℎ−1,0 + 𝜔𝐼1
1,ℎ,0 − 𝛾ℎ𝐼1
0,ℎ,0 − 𝑅𝑛𝑓1𝐼1
0,ℎ,0 − 𝜙ℎ𝐼1
0,ℎ,0 − 𝜁1𝐼1
0,ℎ,0  for h = 
2, 3, 4;  r = 1, 2, 3 
iv. 
𝑑𝐼𝑐
0,ℎ,0
𝑑𝑡
= 𝜋ℎ𝜆𝑐
𝑟𝑆𝑐
0 + 𝛾ℎ−1𝐼𝑐
0,ℎ−1,0 + 𝜁𝑐−1𝐼𝑐−1
0,ℎ,0 + 𝜔𝐼𝑐
1,ℎ,0 − 𝛾ℎ𝐼𝑐
0,ℎ,0 − 𝑅𝑛𝑓𝑐𝐼𝑐
0,ℎ,0 − 𝜙ℎ𝐼𝑐
0,ℎ,0 −
𝜁𝑐𝐼𝑐
0,ℎ,0 for c = 2, 3, 4; h = 2,3, 4;  r = 1, 2, 3 
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On ART  
i. 
𝑑𝐼1
0,1,1
𝑑𝑡
= 𝜙1𝐼1
0,1,0 + 𝜈𝜔𝐼1
1,1,1 − 𝜑𝛾1𝐼1
0,1,1 − 𝑅𝑥𝑅𝑛𝑓1𝐼1
0,1,1 − ψ0,1𝐼1
0,1,1 − 𝜁1𝐼1
0,1,1 
ii. 
𝑑𝐼𝑐
0,1,1
𝑑𝑡
= 𝜙1𝐼𝑐
0,1,0 + 𝜁𝑐−1𝐼𝑐−1
0,1,1 + 𝜈𝜔𝐼𝑐
1,1,1 − 𝜑𝛾1𝐼𝑐
0,1,1 − 𝑅𝑥𝑅𝑛𝑓𝑐𝐼𝑐
0,1,1 − 𝜓0,1𝐼𝑐
0,1,1 − 𝜁𝑐𝐼𝑐
0,1,1 
 for c = 2, 3, 4 
iii. 
𝑑𝐼1
0,ℎ,1
𝑑𝑡
= 𝜑𝛾ℎ−1𝐼1
0,ℎ−1,1 + 𝜙ℎ𝐼1
0,ℎ,0 + 𝜈𝜔𝐼1
1,ℎ,1 − 𝜑𝛾ℎ𝐼1
0,ℎ,1 − 𝑅𝑥𝑅𝑛𝑓1𝐼1
0,ℎ,1 − ψ0,ℎ𝐼1
0,ℎ,1 −
𝜁1𝐼1
0,ℎ,1 for h= 2, 3 
iv. 
𝑑𝐼𝑐
0,ℎ,1
𝑑𝑡
= 𝜑𝛾ℎ−1𝐼𝑐
0,ℎ−1,1 + 𝜙ℎ𝐼𝑐
0,ℎ,0 + 𝜁𝑐−1𝐼𝑐−1
0,ℎ,1 + 𝜈𝜔𝐼𝑐
1,ℎ,1 − 𝜑𝛾ℎ𝐼𝑐
0,ℎ,1 − 𝑅𝑥𝑅𝑛𝑓𝑐𝐼𝑐
0,ℎ,1 −
ψ0,ℎ𝐼𝑐
0,ℎ,1 − 𝜁𝑐𝐼𝑐
0,ℎ,1  for c = 2,3,4 ;    h = 2, 3 
v. 
𝑑𝐼1
0,4,1
𝑑𝑡
= 𝜑𝛾3𝐼1
0,3,1 + ϕ4𝐼1
0,4,0 + 𝜙4𝐼1
0,4,2 + 𝜈𝜔𝐼1
1,4,1 − 𝑅𝑥𝑅𝑛𝑓1𝐼1
0,4,1 − ψ0,4𝐼1
0,4,1 − 𝜁1𝐼1
0,4,1 −
𝜑𝛾4𝐼1
0,4,1 
vi. 
𝑑𝐼𝑐
0,4,1
𝑑𝑡
= 𝜑𝛾3𝐼𝑐
0,3,1 + ϕ4𝐼𝑐
0,4,0 + 𝜙 .4𝐼𝑐
0,4,2 + 𝜁𝑐−1𝐼𝑐−1
0,4,1 + 𝜈𝜔𝐼𝑐
1,4,1 − 𝑅𝑥𝑅𝑛𝑓𝑐𝐼𝑐
0,4,1 − ψ0,4𝐼𝑐
0,4,1 −
𝜁𝑐𝐼𝑐
0,4,1 − 𝜑𝛾4𝐼𝑐
0,4,1  for c = 2,3,4 
 
ART dropouts   
i. 
𝑑𝐼1
0,1,2
𝑑𝑡
= 𝜓0,1𝐼1
0,1,1 + 𝜔𝐼1
1,1,2 + (1 − 𝜈)𝜔𝐼1
1,1,1 − 𝛾1𝐼1
0,1,2 − 𝑅𝑛𝑓1𝐼1
0,1,2 − 𝜁1𝐼1
0,1,2 
ii. 
𝑑𝐼𝑐
0,1,2
𝑑𝑡
= 𝜓0,1𝐼𝑐
0,1,1 + 𝜁𝑐−1𝐼𝑐−1
0,1,2 + 𝜔𝐼𝑐
1,1,2 + (1 − 𝜈)𝜔𝐼𝑐
1,1,1 − 𝛾1𝐼𝑐
0,1,2 − 𝑅𝑛𝑓𝑐𝐼𝑐
0,1,2 − 𝜁𝑐𝐼𝑐
0,1,2 
 for c = 2, 3, 4 
iii. 
𝑑𝐼1
0,ℎ,2
𝑑𝑡
= 𝛾ℎ−1𝐼1
0,ℎ−1,2 + ψ0,ℎ𝐼1
0,ℎ,1 + 𝜔𝐼1
1,ℎ,2 + (1 − 𝜈)𝜔𝐼1
1,ℎ,1 − 𝛾ℎ𝐼1
0,ℎ,2 − 𝑅𝑛𝑓1𝐼1
0,ℎ,2 − 𝜁1𝐼1
0,ℎ,2 
 for h = 2, 3 
iv. 
𝑑𝐼𝑐
0,ℎ,2
𝑑𝑡
= 𝛾ℎ−1𝐼𝑐
0,ℎ−1,2 + ψ0,ℎ𝐼𝑐
0,ℎ,1 + 𝜁𝑐−1𝐼𝑐−1
0,ℎ,2 + 𝜔𝐼𝑐
1,ℎ,2 + (1 − 𝜈)𝜔𝐼𝑐
1,ℎ,1 − 𝛾ℎ𝐼𝑐
0,ℎ,2 −
𝑅𝑛𝑓𝑐𝐼𝑐
0,ℎ,2 − 𝜁𝑐𝐼𝑐
0,ℎ,2  for c = 2, 3, 4; h = 2, 3 
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v. 
𝑑𝐼1
0,4,2
𝑑𝑡
= 𝛾3𝐼1
0,3,2 + ψ0,4𝐼1
0,4,1 + 𝜔𝐼1
1,4,2 + (1 − 𝜈)𝜔𝐼1
1,4,1 − 𝑅𝑛𝑓1𝐼1
0,4,2 − ϕ0.4𝐼1
0,4,2 − 𝜁1𝐼1
0,4,2 −
𝛾4𝐼1
0,4,2 
vi. 
𝑑𝐼𝑐
0,4,2
𝑑𝑡
= 𝛾3𝐼𝑐
0,3,2 + ψ0,4𝐼𝑐
0,4,1 + 𝜁𝑐−1𝐼𝑐−1
0,4,2 + 𝜔𝐼𝑐
1,4,2 + (1 − 𝜈)𝜔𝐼𝑐
1,4,1 − 𝑅𝑛𝑓𝑐𝐼𝑐
0,4,2 − ϕ0,4𝐼𝑐
0,4,2 −
𝜁𝑐𝐼𝑐
0,4,2 − 𝛾4𝐼𝑐
0,4,2  for c = 2, 3, 4 
 
d. Currently pregnant/breastfeeding HIV infected women  
ART naïve  
i. 
𝑑𝐼1
1,1,0
𝑑𝑡
= 𝜋1𝜛𝜆1
𝑟𝑆1
1 + 𝑅𝑛𝑓1𝐼1
0,1,0 − 𝛾1𝐼1
1,1,0 − 𝜔𝐼1
1,1,0 − 𝑥𝑏1𝐼1
1,1,0 − 𝜁1𝐼1
1,1,0   
 for r = 1, 2, 3 
ii. 
𝑑𝐼𝑐
1,1,0
𝑑𝑡
= 𝜋1𝜛𝜆𝑐
𝑟𝑆𝑐
1 + 𝜁𝑐−1𝐼𝑐−1
1,1,0 + 𝑅𝑛𝑓𝑐𝐼𝑐
0,1,0 − 𝛾1𝐼𝑐
1,1,0 − 𝜔𝐼𝑐
1,1,0 − 𝑥𝑏1𝐼𝑐
1,1,0 − 𝜁𝑐𝐼𝑐
1,1,0  for c = 
2, 3, 4;   r = 1, 2, 3 
iii. 
𝑑𝐼1
1,ℎ,0
𝑑𝑡
= 𝜋ℎ𝜛𝜆1
𝑟𝑆1
1 + 𝛾ℎ−1𝐼1
1,ℎ−1,0 + 𝑅𝑛𝑓1𝐼1
0,ℎ,0 − 𝛾ℎ𝐼1
1,ℎ,0 − 𝜔𝐼1
1,ℎ,0 − 𝑥𝑏ℎ𝐼1
1,ℎ,0 − 𝜁1𝐼1
1,ℎ,0  
 for h = 2, 3, 4;  r = 1, 2, 3 
iv. 
𝑑𝐼𝑐
1,ℎ,0
𝑑𝑡
= 𝜋ℎ𝜛𝜆𝑐
𝑟𝑆𝑐
1 + 𝛾ℎ−1𝐼𝑐
1,ℎ−1,0 + 𝜁𝑐−1𝐼𝑐−1
1,ℎ,0 + 𝑅𝑛𝑓𝑐𝐼𝑐
0,ℎ,0 − 𝛾ℎ𝐼𝑐
1,ℎ,0 − 𝜔𝐼𝑐
1,ℎ,0 − 𝑥𝑏ℎ𝐼𝑐
1,ℎ,0 −
𝜁𝑐𝐼𝑐
1,ℎ,0 for c = 2, 3, 4;  h = 2, 3, 4;  r = 1, 2, 3 
 
On ART  
i. 
𝑑𝐼1
1,1,1
𝑑𝑡
= 𝑥𝑏1𝐼1
1,1,0 + 𝑥𝑏1𝐼1
1,1,2 + 𝑅𝑥𝑅𝑛𝑓1𝐼1
0,1,1 − 𝜑𝛾1𝐼1
1,1,1 − 𝜈𝜔𝐼1
1,1,1 − (1 − 𝜈)𝜔𝐼1
1,1,1 −
𝜓1,1𝐼1
1,1,1 − 𝜁1𝐼1
1,1,1 
ii. 
𝑑𝐼𝑐
1,1,1
𝑑𝑡
=  𝑥𝑏1𝐼𝑐
1,1,0 + 𝑥𝑏1𝐼𝑐
1,1,2 +  𝜁𝑐−1𝐼𝑐−1
1,1,1 + 𝑅𝑥𝑅𝑛𝑓𝑐𝐼𝑐
0,1,1 − 𝜑𝛾1𝐼𝑐
1,1,1 − 𝜈𝜔𝐼𝑐
1,1,1 −
(1 − 𝜈)𝜔𝐼𝑐
1,1,1 − 𝜓1,1𝐼𝑐
1,1,1 − 𝜁𝑐𝐼𝑐
1,1,1 for c = 2, 3, 4 
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iii. 
𝑑𝐼1
1,ℎ,1
𝑑𝑡
= 𝜑𝛾ℎ−1𝐼1
1,ℎ−1,1 + 𝑥𝑏ℎ𝐼1
1,ℎ,0 + 𝑥𝑏ℎ𝐼1
1,ℎ,2 + 𝑅𝑥𝑅𝑛𝑓1𝐼1
0,ℎ,1 − 𝜑𝛾ℎ𝐼1
1,ℎ,1 − 𝜈𝜔𝐼1
1,ℎ,1 − (1 −
𝜈)𝜔𝐼1
1,ℎ,1 − 𝜓1,ℎ𝐼1
1,ℎ,1 − 𝜁1𝐼1
1,ℎ,1   for c = 1 and h = 2, 3, 4 
iv. 
𝑑𝐼𝑐
1,ℎ,1
𝑑𝑡
= 𝜑𝛾ℎ−1𝐼𝑐
1,ℎ−1,1 + 𝑥𝑏ℎ𝐼𝑐
1,ℎ,0 + 𝑥𝑏ℎ𝐼𝑐
1,ℎ,2 + 𝜁𝑐−1𝐼𝑐−1
1,ℎ,1 + 𝑅𝑥𝑅𝑛𝑓𝑐𝐼𝑐
0,ℎ,1 − 𝜑𝛾ℎ𝐼𝑐
1,ℎ,1 −
𝜈𝜔𝐼𝑐
1,ℎ,1 − (1 − 𝜈)𝜔𝐼𝑐
1,ℎ,1 − 𝜓1,ℎ𝐼𝑐
1,ℎ,1 − 𝜁𝑐𝐼𝑐
1,ℎ,1  for c = 2, 3, 4; h = 2, 3, 4 
 
ART dropouts 
i. 
𝑑𝐼1
1,1,2
𝑑𝑡
=  𝜓1,1𝐼1
1,1,1 + 𝑅𝑛𝑓1𝐼1
0,1,2 − 𝛾1𝐼1
1,1,2 − 𝜔𝐼1
1,1,2 − 𝑥𝑏1𝐼1
1,1,2 − 𝜁1𝐼1
1,1,2 
ii. 
𝑑𝐼𝑐
1,1,2
𝑑𝑡
=  𝜓1,1𝐼𝑐
1,1,1 + 𝜁𝑐−1𝐼𝑐−1
1,1,2 + 𝑅𝑛𝑓𝑐𝐼𝑐
0,1,2 − 𝛾1𝐼𝑐
1,1,2 − 𝜔𝐼𝑐
1,1,2 − 𝑥𝑏1𝐼𝑐
1,1,2 − 𝜁𝑐𝐼𝑐
1,1,2  
 for c = 2,3,4 
iii. 
𝑑𝐼1
1,ℎ,2
𝑑𝑡
= 𝛾ℎ−1𝐼1
1,ℎ−1,2 + 𝜓1,ℎ𝐼1
1,ℎ,1 + 𝑅𝑛𝑓1𝐼1
0,ℎ,2 − 𝛾ℎ𝐼1
1,ℎ,2 − 𝜔𝐼1
1,ℎ,2 − 𝑥𝑏,ℎ𝐼1
1,ℎ,2 − 𝜁1𝐼1
1,ℎ,2   
 for c=1 and h= 2, 3, 4 
iv. 
𝑑𝐼𝑐
1,ℎ,2
𝑑𝑡
= 𝛾ℎ−1𝐼𝑐
1,ℎ−1,2 + 𝜓1,ℎ𝐼𝑐
1,ℎ,1 + 𝜁𝑐−1𝐼𝑐−1
1,ℎ,2 + 𝑅𝑛𝑓𝑐𝐼𝑐
0,ℎ,2 − 𝛾ℎ𝐼𝑐
1,ℎ,2 − 𝜔𝐼𝑐
1,ℎ,2 − 𝑥𝑏ℎ𝐼𝑐
1,ℎ,2 −
𝜁𝑐𝐼𝑐
1,ℎ,2   for c = 2, 3, 4; h= 2, 3, 4 
 
HIV incidence rate among women 
Age – and calendar time-specific HIV incidence rates 𝜆𝑐(𝑡) among not pregnant women were 
derived from the total calendar time-specific HIV incidence rates Λ(𝑡) in the population, relative 
HIV incidence comparing women in age cohort c to age cohort 3  𝛿𝑐, and relative HIV incidence 
comparing pregnant / breastfeeding women to not pregnant women 𝜛  as follows: 
Λ(𝑡) =  
(𝛿1(𝑆1
0 + 𝜛𝑆1
1) + 𝛿2(𝑆2
0 + 𝜛𝑆2
1) + (𝑆3
0 + 𝜛𝑆3
1) + 𝛿4(𝑆4
0 + 𝜛𝑆4
1)) 𝜆3(𝑡)
∑ ∑ 𝑆𝑐
𝑝1
𝑝=0
4
𝑐=1
 
𝜆3(𝑡) =
Λ(𝑡) ∑ ∑ 𝑆𝑐
𝑝1
𝑝=0
4
𝑐=1
𝛿1(𝑆1
0 + 𝜛𝑆1
1) + 𝛿2(𝑆2
0 + 𝜛𝑆2
1) + (𝑆3
0 + 𝜛𝑆3
1) + 𝛿4(𝑆4
0 + 𝜛𝑆4
1)
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Fertility 
Age- and calendar time-specific fertility rate for HIV negative  𝑓𝑐 , HIV positive but not on ART 
𝑓𝑐𝑥
0  , and HIV positive on ART  𝑓𝑐𝑥
1  were derived from total age- and calendar time-specific 
fertility rate 𝑓𝑐𝑇 using fertility rate ratios 𝑅
𝑛 comparing fertility rates in HIV positive to fertility rates 
in HIV negative women and fertility rate ratios  𝑅𝑥  comparing fertility rates in HIV positive 
women on ART to HIV positive women not on ART as follows: 
𝑓𝑐𝑇 =
(𝑆𝑐
𝑜 + 𝑅𝑛 ∑ (𝐼𝑐
0,ℎ,0 + 𝐼𝑐
0,ℎ,2) + 𝑅𝑥𝑅𝑛 ∑ 𝐼𝑐
0,ℎ,14
ℎ=1
4
ℎ=1 )𝑓𝑐
𝑁𝑐
0  
where     𝑁𝑐
0 =   𝑆𝑐
0 + ∑ (𝐼𝑐
0,ℎ,0 + 𝐼𝑐
0,ℎ,1 + 𝐼𝑐
0,ℎ,2)4ℎ=1 ,  c = 1, 2, 3, 4 
𝑓𝑐 =  
𝑓𝑐𝑇𝑁𝑐
0
𝑆𝑐
𝑜 + 𝑅𝑛 ∑ (𝐼𝑐
0,ℎ,0 + 𝐼𝑐
0,ℎ,2) + 𝑅𝑥𝑅𝑛 ∑ 𝐼𝑐
0,ℎ,14
ℎ=1
4
ℎ=1
 
 
HIV transmission from women to men 
HIV-infected women will infect their male sexual partners at a constant transmission rate  𝛽(𝑡) 
that will be modified by relative infectiousness due to disease stage 𝜌ℎ, ART treatment 𝜅, and 
pregnancy status 𝛼 with asymptomatic stage 1, not on ART, and not pregnant women as 
referent. 
Total HIV incidence in men (IM): 
 
𝐼𝑀 = 𝛽(𝑡) ∑ ∑ 𝜌ℎ4ℎ=1
4
𝑐=1 {(𝐼𝑐
0,ℎ,0 + 𝛼𝐼𝑐
1,ℎ,0 ) + (𝐼𝑐
0,ℎ,2 + 𝛼𝐼𝑐
1,ℎ,2) + 𝜅(𝐼𝑐
0,ℎ,1 + 𝛼𝐼𝑐
1,ℎ,1)}  
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APPENDIX 2: AIM 2 SUPPLEMENTAL TABLES 
Table A2.1 HIV incidence rates  
 
Year 
 
Incidence rate  
1990 Normal(0.0229, 0.0013) 
1991 Normal(0.0243, 0.0011) 
1992 Normal(0.0248, 0.0011) 
1993 Normal(0.0249, 0.0011) 
1994 Normal(0.0242, 0.0011) 
1995 Normal(0.0233, 0.0009) 
1996 Normal(0.0224, 0.0008) 
1997 Normal(0.0212, 0.0008) 
1998 Normal(0.0200, 0.0007) 
1999 Normal(0.0187, 0.0007) 
2000 Normal(0.0174, 0.0006) 
2001 Normal(0.0161, 0.0006) 
2002 Normal(0.0150, 0.0005) 
2003 Normal(0.0138, 0.0005) 
2004 Normal(0.0128, 0.0004) 
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Table A2.1 HIV incidence rates (continued)  
2005 Normal(0.0117, 0.0004) 
2006 Normal(0.0107, 0.0004) 
2007 Normal(0.0098, 0.0004) 
2008 Normal(0.0089, 0.0005) 
2009 Normal(0.0080, 0.0004) 
2010 Normal(0.0073, 0.0005) 
2011 Normal(0.0066, 0.0005) 
2012 Normal(0.0058, 0.0004) 
2013 Normal(0.0051, 0.0004) 
2014 Normal(0.0045, 0.0004) 
 
 
Table A2.2 Proportion eligible to continue on ART after breastfeeding 
 
CD4  
 
ART for Health Eligibility Criteria 
Option B Option B+ 
< 250 < 350 < 500 < 350 < 500 
≥500 0 0 0 1 1 
350 - 499 0 0 1 1 1 
200 - 349 Uniform(0.33, 0.50) 1 1 1 1 
< 200 1 1 1 1 1 
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Table A2.3 Age – and calendar-specific fertility rates (US Census Bureau)  
Year Age 
 15-19 20-24 25-34 35-49 
1977 0.1682 0.3384 0.3025 0.1440 
1978 0.1682 0.3384 0.3025 0.1440 
1979 0.1682 0.3384 0.3025 0.1440 
1980 0.1682 0.3384 0.3025 0.1440 
1981 0.1682 0.3384 0.3025 0.1440 
1982 0.1682 0.3384 0.3025 0.1440 
1983 0.1684 0.3309 0.2963 0.1420 
1984 0.1686 0.3234 0.2901 0.1401 
1985 0.1688 0.3159 0.2839 0.1382 
1986 0.1690 0.3084 0.2776 0.1363 
1987 0.1692 0.3009 0.2714 0.1344 
1988 0.1694 0.2934 0.2652 0.1324 
1989 0.1696 0.2945 0.2634 0.1295 
1990 0.1699 0.2955 0.2616 0.1267 
1991 0.1701 0.2966 0.2598 0.1238 
1992 0.1703 0.2976 0.258 0.1209 
1993 0.1706 0.2987 0.2563 0.1180 
1994 0.1708 0.2997 0.2544 0.1151 
1995 0.1711 0.3008 0.2527 0.1122 
 
 
 
 86 
 
Table A2.3 Age – and calendar-specific fertility rates (US Census Bureau) (continued)  
1996 0.1713 0.3018 0.2509 0.1093 
1997 0.1715 0.3029 0.2491 0.1064 
1998 0.1718 0.3039 0.2473 0.1036 
1999 0.1720 0.3050 0.2455 0.1007 
2000 0.1689 0.3003 0.2428 0.0990 
2001 0.1666 0.2969 0.2409 0.0979 
2002 0.1643 0.2936 0.2390 0.0968 
2003 0.1621 0.2902 0.2371 0.0956 
2004 0.1598 0.2868 0.2351 0.0944 
2005 0.1598 0.2868 0.2351 0.0944 
2006 0.1598 0.2868 0.2351 0.0944 
2007 0.1598 0.2868 0.2351 0.0944 
2008 0.1598 0.2868 0.2351 0.0944 
2009 0.1578 0.2838 0.2334 0.0934 
2010 0.1558 0.2808 0.2317 0.0924 
2011 0.1538 0.2779 0.2300 0.0913 
2012 0.1518 0.2749 0.2283 0.0903 
2013 0.1499 0.2719 0.2266 0.0893 
2014 0.1479 0.2689 0.2249 0.0883 
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Table A2.4 Mean duration of any breastfeeding (months) 
 Year 
1992 2000 2004 2010 
Mean duration of 
breastfeeding 
20.2 22.6 23.1 23.0 
 
Table A2.5 Percent of pregnant women who received antenatal care from a skilled 
provider by age 
Age Year 
 1992 2000 2004 2010 
15 -19 91.9 93.4 92.5 95.6 
20 - 24 91.3 91.9 92.4 94.6 
25 - 34 91.3 91.9 92.4 94.6 
35 - 49 85.2 87.0 90.7 93.8 
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